WO2019236757A1 - Methods of treating conditions related to the s1p1 receptor - Google Patents

Methods of treating conditions related to the s1p1 receptor Download PDF

Info

Publication number
WO2019236757A1
WO2019236757A1 PCT/US2019/035662 US2019035662W WO2019236757A1 WO 2019236757 A1 WO2019236757 A1 WO 2019236757A1 US 2019035662 W US2019035662 W US 2019035662W WO 2019236757 A1 WO2019236757 A1 WO 2019236757A1
Authority
WO
WIPO (PCT)
Prior art keywords
substrate
inhibitor
compound
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/035662
Other languages
English (en)
French (fr)
Inventor
Ronald J. Christopher
Abu J.M. Sadeque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67253955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2019236757(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2019280822A priority Critical patent/AU2019280822A1/en
Priority to BR112020024762-6A priority patent/BR112020024762A2/pt
Priority to ES19739424T priority patent/ES2987794T3/es
Priority to CA3102136A priority patent/CA3102136A1/en
Priority to KR1020217000401A priority patent/KR102859841B1/ko
Priority to US15/734,920 priority patent/US12156866B2/en
Priority to JP2020567825A priority patent/JP7397011B2/ja
Priority to EP19739424.0A priority patent/EP3801459B1/en
Priority to CN201980051786.0A priority patent/CN112601516A/zh
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Priority to MX2020013157A priority patent/MX2020013157A/es
Publication of WO2019236757A1 publication Critical patent/WO2019236757A1/en
Priority to IL279180A priority patent/IL279180A/en
Anticipated expiration legal-status Critical
Priority to US18/964,847 priority patent/US20250090497A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • sphingosine 1 -phosphate subtype 1 SIPi or SIPI
  • the sphingosine-l-phosphate (SIP) receptors 1-5 constitute a family of G protein-coupled receptors with a seven-transmembrane domain. These receptors, referred to as SIPi to SIPs (formerly termed endothelial differentiation gene (EDG) receptor-1, -5, -3, -6, and -8, respectively; Chun et a!.. Pharmacological Reviews, 54:265-269, 2002), are activated via binding by sphingosine-l-phosphate, winch is produced by tire sphingosine kinase-catalyzed phosphorylation of sphingosine.
  • SIPi to SIPs (formerly termed endothelial differentiation gene (EDG) receptor-1, -5, -3, -6, and -8, respectively; Chun et a!.. Pharmacological Reviews, 54:265-269, 2002)
  • SIPs, Sll and S IP5 receptors activate Gi but not Gq
  • SIP 2 and SIP 3 receptors activate both Gi and Gq.
  • the SIP 3 receptor, but not the SIPs receptor, responds to an agonist with an increase in intracellular calcium .
  • agonists useful in the treatment of SI Pi receptor-associated disorders the compound ⁇ R)-2 -(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l, 2,3,4- tetrahydrocyclopenta[0]indo! ⁇ 3-yl)acetic acid (Compound 1, APD334) , or a pharmaceutically acceptable salt, solvate, or hydrate thereof,
  • Compound 1 is an investigational drug candidate intended for the treatment of sphingosine 1- phosphate subtype 1 (SlPi) receptor-associated disorders.
  • SI Pi agonists cause side effects, and particularly cardiovascular related adverse events, that require that doctors titrate patients slowly to a maintenance dose. This titration period can take weeks or even a month. The complexity and length of the titration regimen may result in prematurely discontinuing therapy by patients prior to reaching the maintenance dose or to doctors preferring other therapeutic options.
  • a method of treating an individual with a sphingosine 1 -phosphate subtype 1 (S J P i) receptor-associated disorder comprising: administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of (i?)-2-(7-(4-cyclopentyl-3- (trifluorometiiyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[6]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25.
  • SI Pi sphingosine 1 -phosphate subtype 1
  • Compound 1 chosen from (R) ⁇ 2-(7 -(4 -cyclopentyl-3
  • Pgp P -glycoprotein
  • BCRP breast cancer resistance protein
  • OATPIBI
  • Figure 1 shows the mean plasma concentration-time profiles for the tablet formulation of Compound 1 administered under fed versus fasted conditions.
  • COMPOUND 1 As used herein,“Compound 1” means (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[Z>]indol-3-yl)acetic acid including crystalline forms thereof. As a non-limiting example, Compound 1 may be present as an anhydrous, non-solvated crystalline form as described in WO 2010/011316 (incorporated by reference herein in its entirety).
  • an L-arginine salt of Compound 1 may be present as an anhydrous, non- solvated crystalline form as described in WO 2010/011316 and WO 2011/094008 (each of winch is incorporated by reference herein in its entirety').
  • a calcium salt of Compound 1 may be present as a crystalline form as described in WO 2010/011316 (incorporated by reference herein m its entirety).
  • ADMINISTERING means to provide a compound or other therapy, remedy, or treatment such that an individual internalizes a compound.
  • CO-ADMINISTER As used herein, "co-administer” and “co-administration” and variants thereof mean the administration of at least two drugs to a patient either subsequently, simultaneously, or consequently proximate in time to one another (e.g., within the same day, or week or period of 30 days, or sufficiently proximate that each of the at least two drugs can be simultaneously detected in the blood plasma).
  • two or more active agents can be co-formulated as part of the same composition or administered as separate formulations. This also may be referred to herein as
  • PRESCRIBING means to order, authorize, or recommend the use of a drag or other therapy, remedy, or treatment.
  • a health care practitioner can orally advise, recommend, or authorize the use of a compound, dosage regimen or other treatment to an individual.
  • the health care practitioner may or may not provide a prescription for the compound, dosage regimen, or treatment. Further, the health care practitioner may or may not provide the
  • a health care practitioner can advise the individual where to obtain the compound without providing the compound.
  • a health care practitioner can provide a prescription for the compound, dosage regimen, or treatment to the individual.
  • a health care practitioner can give a written or oral prescription to an individual.
  • a prescription can be written on paper or on electronic media such as a computer file, for example, on a hand held computer device.
  • a health care practitioner can transform a piece of paper or electronic media with a prescription for a compound, dosage regimen, or treatment.
  • a prescription can be called in (oral), faxed in (written), or submitted electronically via the internet to a pharmacy or a dispensary.
  • a sample of the compound or treatment can be given to the individual.
  • a prescription can include, for example, an individual’s name and/or identifying information such as date of birth .
  • a prescription can include: the medication name, medication strength, dose, frequency of administration, route of administration, number or amount to be dispensed, number of refills, physician name, physician signature, and the like.
  • a prescription can include a DBA number and/or state number.
  • a healthcare practitioner can include, for example, a physician, nurse, nurse practitioner, or other related heal th care professional who can prescribe or administer compounds (drags) for the treatment of a sphingosine 1-phosphate subtype 1 (S IPi) receptor-associated disorder.
  • a healthcare practitioner can include anyone who can recommend, prescribe, administer, or prevent an individual from receiving a compound or drag including, for example, an insurance provider.
  • the term“prevent,” “preventing”, or“prevention” such as prevention of a sphingosine 1 -phosphate subtype 1 (SI P receptor- associated disorder or the occurrence or onset of one or more symptoms associated with the particular disorder and does not necessarily mean the complete prevention of the disorder.
  • the term‘prevent,”“preventing” and“prevention” means the administration of therapy on a prophylactic or preventative basis to an individual who may ultimately manifest at least one symptom of a disease or condition but who has not yet done so. Such individuals can be identified on the basis of risk factors that are known to correlate with tire subsequent occurrence of the disease. Alternatively, prevention therapy can be administered without prior identification of a risk factor, as a prophylactic measure . Delaying the onset of at least one symptom can also be considered prevention or prophylaxis.
  • the tenn“treat,”“treating”, or “treatment” means the administration of therapy to an individual who already manifests at least one symptom of a disease or condition or who has pre viously manifested at least one symptom of a disease or condition.
  • “treating” can include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving die disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition.
  • the tenn“treating” in reference to a disorder means a reduction in severity of one or more symptoms associated with that particular disorder. Therefore, treating a disorder does not necessarily mean a reduction in severity' of ail symptoms associated with a disorder and does not necessarily mean a complete reduction m the severity of one or more symptoms associated with a disorder.
  • TOLERATE A s used herein, an individual is said to“tolerate” a dose of a compound if administration of that dose to that individual does not result in an unacceptable adverse event or an unacceptable combination of adverse events.
  • tolerance is a subjective measure and that what may be tolerable to one individual may not be tolerable to a different individual . For example, one individual may not be able to tolerate headache, whereas a second individual may find headache tolerable but is not able to tolerate vomiting, whereas for a third individual, either headache alone or vomiting alone is tolerable, but the indi vidual is not able to tolerate the combination of headache and vomiting, even if the severity of each is less than when experienced alone.
  • an“adverse event” is an untoward medical occurrence that is associated with treatment with Compound 1 or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
  • an adverse event is selected from: leukopenia, constipation, diarrhea, nausea, abdominal pain, neutropenia, vomiting, back pain, and menstrual disorder.
  • an adverse event is heart block, for example, a first-degree atrioventricular heart block.
  • an adverse event is an acute heart rate reduction.
  • an adverse event is an abnormal pulmonary' ⁇ function test finding, such as an FEY 1 below 80%, FVC.
  • an adverse event is an abnormal liver function test, such as an elevated ALT & AST>2X ULN.
  • an adverse event is macular edema.
  • INDIVIDUAL As used herein,“individual” means any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates and most preferably humans. In some embodiments, a human individual is referred to a“patient.”
  • acute heart rate reduction means a heart rate decrease from normal sinus rhythm of, for example, 10 or more beats per minute (bpm), such as less than about 5 bpm, e.g., less than about 4 bpm or less than about 3 bpm or less than 2 bpm, that is maximal within a few hours, for example 1-3 hours, after drug administration, and thereafter the heart rate returns towards the pre-dose value.
  • bpm beats per minute
  • NORMAL SINUS RHYTHM As used herein,“normal sinus rhythm” means the sinus rhythm of the individual when not undergoing treatment. The evaluation of normal sinus rhythm is within the ability of a physician. A normal sinus rhythm will generally give rise to a heart rate in the range from 60-100 bpm.
  • DOSE As used herein,“dose” means a quantity of Compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, given to the individual for treating or preventing the disease or disorder at one specific time
  • standard dose means the dose of Compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, that is given to the individual for treating or preventing the disease or disorder.
  • administration of the standard dose achieves a target reduction in peripheral blood lymphocyte counts, e.g., a reduction baseline of at least 35%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%.
  • administration of the standard dose achieves a reduction in baseline of about 35% to about 70%, such as about 40% to about 65%, such as about 50% to about 65%.
  • administration of the standard dose achieves target peripheral blood lymphocyte counts, e.g., less than 1000 lymphocytes per microliter, such as 400-800 lymphocytes per microliter.
  • the target dose may vary depending on the nature and severity of the disease to be treated.
  • THERAPEUTICALLY EFFECTIVE AMOUNT As used herein, "therapeutically effective amount" of an agent, compound, drug, composition or combination is an amount which is nontoxic and effective for producing some desired therapeutic effect upon administration to a subject or patient (e.g., a human subject or patient).
  • the precise therapeutically effective amount for a subject may depend upon, e.g., the subject’s size and health, the nature and extent of the condition, the therapeutics or combination of therapeutics selected for administration, and other variables known to those of skill in the art.
  • the effecti ve amount for a given situation is determined by routine experimentation and is within the judgment of the clinician.
  • the therapeutically effective amount is the standard dose.
  • fasted individual means an individual who has not eaten any food, i.e., has fasted for at least 6-8 hours, such as about 8 hours, before the administration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and who does not eat any food and continues to fast for at least 1 hour after the administration of Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
  • the individual may also refrain from ingesting certain non-food substances during the fasting period. For example, in certain embodiments tire individual does not ingest any supplements and/or drugs during the fasting period.
  • the individual does not ingest any high calorie liquids during the fasting period. In certain embodiments, the individual does not ingest any liquids other than water during the fasting period. In certain embodiments, the individual may ingest small amounts of low-calorie beverages, such as tea, coffee, or diluted juices.
  • the 6-point Mayo score is based on stool frequency and rectal bleeding PROs collected daily using electronic patient diaries and excludes the findings on endoscopy and the physician’s global assessment.
  • the 3-point Mayo score is based on stool frequency, rectal bleeding, and findings on endoscopy and has a total score ranging from 0 to 9.
  • the 2- point Mayo score is based on rectal bleeding and findings on endoscopy and has a total score ranging from 0 to 6.
  • the physician’s global assessment acknowledges the three other criteria findings of the MCS, the individual’s daily record of abdominal discomfort and general sense of well-being, and other observations, such as physical findings and the individual’s performance.
  • MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS means ulcerative colitis characterized by a 4-component MCS of 4 to 10
  • ulcerative colitis characterized by a 3-component MCS of 4 to 9 including an endoscopic subscore of > 2 and a rectal bleeding score of > 1.
  • the 3-component MCS uses 3 of the 4 components of the complete MCS (endoscopic findings, rectal bleeding, and stool frequency).
  • CLINICAL REMISSION As used herein,“clinical remission” with respect to ulcerative colitis means a 3-component Mayo Clinic score as follows: an endoscopy score (using flexible
  • proctosigmoidoscopy of 0 or 1
  • rectal bleeding score of 0
  • stool frequency score of 0 or 1 with a decrease of > 1 point from baseline subscore.
  • CLINICAL RESPONSE As used herein,“clinical response” with respect to ulcerative colitis means a reduction in the 3-component Mayo Clinic score of > 2 points and a decrease of > 30% from baseline with an accompanying decrease in rectal bleeding subscore of > 1 or absolute rectal bleeding score of 0 or 1.
  • ENDOSCOPIC IMPROVEMENT As used herein,“endoscopic improvement” with respect to ulcerative colitis means ulcerative colitis characterized by a Mayo endoscopic subscore (using findings of flexible proctosigmoidoscopy) of ⁇ 1 point.
  • IMPROVEMENT IN RECTAL BLEEDING As used herein,“improvement in rectal bleeding” with respect to ulcerative colitis means a change from baseline ⁇ 0.
  • HISTOLOGIC HEALING / HISTOLOGIC IMPROVEMENT As used herein,“histologic healing,”“histological healing,”“histologic improvement,” or“histological improvement” with respect to ulcerative colitis means a score of ⁇ 3.1 on the Geboes Index.
  • HISTOLOGIC REMISSION As used herein,“histologic remission” or“histological remission” with respect to ulcerative colitis means a score of ⁇ 2.0 on the Geboes Index.
  • MUCOSAL HEALING As used herein,“mucosal healing” is both endoscopic improvement and histological remission.
  • IMPROVEMENT IN STOOL FREQUENCY As used herein,“improvement in stool frequency” with respect to ulcerative colitis means a change from baseline ⁇ 0.
  • 5-AMINOSALICYLATES As used herein,“5-aminosalicylates”, means a class of drags that include, for example, CANASA® (mesalamine), COLAZAL® (balsalazide disodium), ASACOL®
  • IMMUNOSUPPRESSIVES means a class of drugs that include, for example, AZASAN® (azathioprine), IMURAN® (azathioprine), GENGRAF® (cyclosporine), NEORAL® (cyclosporine), and SANDIMMUNE® (cyclosporine).
  • GLUCOCORTICOSTEROIDS As used herein,“glucocorticosteroids”, means a class of drugs that include, for example, UCER1S® (budesonide); DELTASONE® (prednisone), MEDROL®
  • TNFa ANTAGONISTS means a class of drugs that include, for example, SIMPONI® (golirnumab), REMICADE® (infliximab), HUMIRA® (adalimumab), and CIMZIA® (certolizumab pegol).
  • INTEGRIN RECEPTOR ANTAGONISTS means a class of drugs that include, for example, ENTYYTO® (vedolizumab).
  • PHARMACEUTICAL COMPOSITION means a composition comprising at least one active ingredient, such as Compound I: including but not limited to, salts, solvates, and hydrates of Compound 1 , whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
  • active ingredient such as Compound I: including but not limited to, salts, solvates, and hydrates of Compound 1
  • a mammal for example, without limitation, a human
  • an agonist means a moiety ' that interacts with and activates a G-protein- coupled receptor, such as the SIP ⁇ , receptor, such as can thereby initiate a physiological or pharmacological response characteristic of that receptor.
  • a G-protein- coupled receptor such as the SIP ⁇
  • an agonist activates an intracellular response upon binding to the receptor or enhances GTP binding to a membrane hi certain embodiments, an agonist of the invention is an S IPi receptor agonist that is capable of facilitating sustained S IPi receptor internalization (see e.g. , Matloubian et ai. Nature, 427, 355, 2004).
  • ANTAGONIST means a moiety that competitively binds to the receptor at the same site as an agonist (for example, the endogenous ligand), but which does not activate the intracellular response initiated by the active form of the receptor and can thereby inhibit the intracellular responses by an agonist or partial agonist.
  • An antagonist does not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
  • inverse agonist means a moiety that binds to tire endogenous fonn of the receptor or to the constitutively activated form of the receptor and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of an agonist or partial agonist, or decreases GTP binding to a membrane.
  • the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%. In some embodiments, the baseline intracellular response is inhibited in die presence of the inverse agonist by at least 50%.
  • the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
  • HYDRATE As used herein,“hydrate” means a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
  • SAFETY POPULATION As used herein,“safety population” means all randomized subjects who received study medication.
  • solvent means a compound of the invention or a salt, thereof, that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.
  • Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts.
  • the compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippunc, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfiric, tartaric, oxalic, -toluenesul tonic and the like, such as those pharmaceutically acceptable salts listed by Berge et al, Journal of Pharmaceutical Sciences , 66: 1-19 (1977), incorporated herein by reference in its entirety.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • Tire compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • “pharmaceutically acceptable solvates and hydrates” or the phrase“pharmaceutically acceptable solvate or hydrate” is used when referring to Compound Ithat are salts, it embraces pharmaceutically acceptable solvates and/or hydrates of such salts.
  • the dosage forms described herein may comprise, as the active component, either Compound 1 or a pharmaceutically acceptable salt or as a solvate or hydrate thereof.
  • various hydrates and solvates of Compound 1 and their salts will find use as intermediates in the manufacture of pharmaceutical compositions. Typical procedures for making and identifying suitable hydrates and solvates, outside those mentioned herein, are well known to those m the art; see for example, pages 202-209 of K.J. Guillory,“Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids,’ in: Polymorphism in Pharmaceutical Solids, ed. Harry G. England, Vol.
  • one aspect of the present disclosure pertains to methods of prescribing and/or administering hydrates and solvates of Compound 1 and/or its pharmaceutical acceptable salts, that can be isolated and characterized by methods known in the art, such as,
  • TGA themiogravimetnc analysis
  • TGA-mass spectroscopy TGA-Infrared spectroscopy
  • XRPD powder X-ray diffraction
  • Karl Fisher titration high resolution X-ray diffraction, and the like.
  • the present disclosure includes all isotopes of atoms occurring in the present compounds, salts, solvates, and hydrates.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • One aspect of the present invention includes every combination of one or more atoms in the present compounds, salts, solvates, and hydrates that is replaced with an atom having the same atomic number but a different mass number.
  • One such example is the replacement of an atom that is the most naturally abundant isotope, such as ⁇ or !2 C, found in one the present compounds, salts, solvates, and hydrates, with a different atom that is not the most naturally abundant isotope, such as 2 H or ⁇ (replacing 3 ⁇ 4), or U C, 13 C, or i4 C (replacing !2 C).
  • a replacement When such a replacement has taken place, it is commonly referred to as being isotopically labeled.
  • Isotopic -labeling of the present compounds, salts, solvates, and hydrates can be accomplished using any one of a variety of different synthetic methods know to those of ordinary skill in the art and they are readily credited with understanding the synthetic methods and available reagents needed to conduct such isotopic -labeling.
  • isotopes of hydrogen include 2 H (deuterium) and 3 H (tritium).
  • Isotopes of carbon include U C, ]3 C, and ]4 C.
  • Isotopes of nitrogen include i3 N and ! , N.
  • Isotopes of oxygen include !:, 0, l7 Q, and !S 0
  • An isotope of fluorine includes I8 F.
  • An isotope of sulfur includes 35 S.
  • An isotope of chlorine includes 36 C1.
  • Isotopes of bromine include 75 Br, /6 Br, / ; Br, and 82 Br.
  • Isotopes of iodine include S23 1, 124 I, u' l, and l S I.
  • compositions such as, those prepared during synthesis, preformulation, and the like, and pharmaceutical compositions, such as, those prepared with the intent of using in a mammal for the treatment of one or more of the disorders described herein, comprising one or more of the present compounds, salts, solvates, and hydrates, wherein the naturally occurring distribution of the isotopes in the composition is perturbed.
  • compositions and pharmaceutical compositions comprising the compounds, salts, solvates, and hydrates, as described herein wherein the salt is enriched at one or more positions with an isotope other than the most naturally abundant isotope.
  • Compounds of the present invention can be converted to“prodrugs.”
  • the tenn“prodrags” means compounds that have been modified with specific chemical groups known in the art and that when administered into an individual undergo biotransformation to give the parent compound.
  • Prodrugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound.
  • the “prodrug” approach is utilized to facilitate oral absorption.
  • T. Higuchi and V. Stella Prodrugs as Novel Delivery Systems Yol. 14 of the A.C.S. Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
  • AUC refers to the area under the curve, or the integral, of the plasma concentration of an active pharmaceutical ingredient or metabolite over time following a dosing event.
  • AUCo- t is the integral under the plasma concentration curve from time 0 (dosing) to time "t" .
  • AUCo- co! is the AUC from time 0 (dosing) to time infinity. Unless otherwise stated, AUC refers to AUCo- ⁇ .
  • Cmax (or C max ) is a pharmacokinetic parameter denoting the maximum observed blood plasma concentration following delivery of an active pharmaceutical ingredient. Cmax occurs at the time of maximum plasma concentration, t max .
  • t max is a pharmacokinetic parameter denoting the time to maximum blood plasma concentration following delivery of an active pharmaceutical ingredient
  • ti, 3 ⁇ 4 is a pharmacokinetic parameter denoting the apparent plasma terminal phase half-life, i.e., the time, after absorption and distribution of a drug is complete, for the plasma concentration to fall by half.
  • a substance having a narrow therapeutic index means a substance falling within any definition of narrow therapeutic index as promulgated by the U.S. Food and Drug Administration or any successor agency thereof, for example, a substance having a less than 2-fold difference in median lethal dose (LD50) and median effective dose (ED50) values or having a less than 2-fold difference in the minimum toxic concentration and minimum effective concentration in the blood; and for which safe and effective use of the substance requires careful titration and patient monitoring.
  • LD50 median lethal dose
  • ED50 median effective dose
  • a substance is a "substrate” of enzyme activity when it can be chemically transformed by action of the enzyme on the substance.
  • Enzyme activity refers broadly to the specific activity of the enzyme (i.e., the rate at which the enzyme transforms a substrate per mg or mole of enzyme) as well as the metabolic effect of such transformations dims
  • a substance is an "inhibitor” of enzyme activity when the specific activity or the metabolic effect of the specific activity of the enzyme can be decreased by the presence of the substance, without reference to the precise mechanism of such decrease.
  • a substance can be an inhibitor of enzyme activity by competitive, non-competitive, allosteric or other type of enzyme inhibition, by decreasing expression of the enzyme, or other direct or indirect mechanisms.
  • a substance is an "inducer" of enzyme activity when the specific activity or the metabolic effect of the specific activity of the enzyme can be increased by the presence of the substance, without reference to the precise mechanism of such increase.
  • a substance can be an inducer of enzyme activity by increasing reaction rate, by increasing expression of the enzyme, by allosteric activation or other direct or indirect mechanisms. Any of these effects on enzyme activity can occur at a given concentration of active agent in a single sample, donor, or patient without regard to clinical significance.
  • a substance can be a substrate, inhibitor, or inducer of an enzyme activity.
  • the substance can be an inhibitor of enzyme activity by one mechanism and an inducer of enzyme activity by another mechanism.
  • the fimction (substrate, inhibitor, or inducer) of the substance with respect to activity of an enzyme can depend on environmental conditions. Lists of inhibitors, inducers and substrates for CYP3A4 can be found, for instance, at
  • composition of mater unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of mater, group of steps, or group of composi tions of mater shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps, or groups of compositions of matter.
  • compositions, and methods are clearly within the scope of the invention(s), as described herein.
  • kits for co-admini storing Compound 1 with another drug are also provided herein. Also provided herein me methods of reducing the dosage of Compound 1 when co-administered with another drug. Also provided herein are methods of reducing the dosage of another drug when co-administered with Compound 1. Also provided herein are methods of discontinuing the administration of Compound 1 when an individual is administered another drug. Also provided herein are methods of discontinuing the administration of another drug when an individual is administered Compound 1. Also provided herein are methods of continuing the administration of Compound 1 when an individual is administered another drug. Also provided herein are methods of continuing the administration of another drug when an indi vidual is administered Compound 1. Also provided herein are methods of monitoring an individual who is co administered Compound 1 and another drug.
  • a method of treating an individual with a sphingosine 1 -phosphate subtype 1 (S lP i) receptor-associated disorder comprising: administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of (i?)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[6]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof wherein the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25.
  • the method further comprises informing the patient or a medical care worker that administration of the S IPi modulator to a patient who is also being administered a CYP2C8 inhibitor, CYP2C9 inhibitor, UDP-glucuronosyltransferase (UGT) enzyme IJGTI AI inhibitor, or UDP- glucuronosyltransferase (UGT) enzyme UGT1A6 inhibitor results in higher exposure of the SI Pi modulator than administration of the S IPi modulator to a patient who is not being administered a CYP2C8 inhibitor, CYP2C9 inhibitor, UDP-glucuronosyltransferase (UGT) enzyme UGT!A! inhibitor, or UDP- glucuronosyltransferase (UGT) enzyme UGT! A6 inhibitor.
  • the method further comprises informing the patient or a medical care worker that administration of the S lPi modulator to a patient who is also being administered a CYP2C8 inhibitor, CYP2C9 inhibitor, UDP-glucuronosyltransferase (UGT) enzyme UGT!A!
  • UDP- glucuronosyltransferase (UGT) enzyme UGT1A6 inhibitor may result in increased risk of one or more exposure-related adverse reactions than administration of the S IPi modulator to a patient who is not being administered a CYP2C8 inhibitor, CYP2C9 inhibitor, UDP-glucuronosyitransferase (UGT) enzyme UGT1A1 inhibitor, or UDP-glucuronosyltransferase (UGT) enzyme UGT1A6 inhibitor.
  • the patient is also being administered a CYP2C8 inhibitor. In some embodiments, the patient is also being administered a CYP2C9 inhibitor. In some embodiments, the patient is also being administered a UDP-glucuronosyltransferase (UGT) enzyme UGT1A1 inhibitor. In some embodiments, the patient is also being administered a UDP-glucuronosyltransferase (UGT) enzyme UGT1A6 inhibitor
  • the CYP2C8 inhibitor is gemfibrozil, ritonavir, clopidogrel, iopinavir, deferasirox, lapatinib, trimethoprim, thiazolidinediones, montelukast, quercetin, candesartan cilexetil (cyclohexylcarbonate ester prodrug of candesartan), zafirlukast, clotrimazole, felodipine, mometasone furoate, salmeterol, raloxifene, fenofihrate, ritonavir, levothyroxine, tamoxifen, loratadine, oxybutynin, medroxyprogesterone, simvastatin, ketoconazole, ethinyl estradiol, spironolactone, lovastatin, nifedipine, or irbes
  • the CYP2C9 inhibitor is amiodarone, disulfram, doxifluridine, efavirenz, fluconazole, imatinib, lefluonomide, metronidazole, miconazole, phenytoin, sulfamethoxazole, sulfapenazone, sildenafil, zafirlukast, valdecoxib, diclofenac, voriconazole, tamoxifen, iosartan, warfarin, etodolac, mefenamic acid, meloxicam, suprofen, irbesartan, ibuprofen, fluvastatin, sertraline, fluvoxamine, pantoprazole, rosiglitazone, lansoprazole, ritonavir, nicardipine, aprepitant, delavirdine, desloratadine, g
  • the CYP2C9 inhibitor is ticlopidine, omeprazole, paroxetine, valsartan, bortezomib, valproic acid, nevirapine, azelastine, lornoxicam, fenofibrate, isomazid, phenylbutazone, probenecid, sulfaphenazole, tcniposide, etravirine, sulfadiazine, sulfinpyrazone, sulfisoxazole,
  • trimethoprim leflunomide, nilotinib, pyrimethamine, sorafenib, capecitabine, fluorouracil, sitaxentan, tranylcypromine, aminophenazone, clopidogrel, verapamil, etoricoxib, propofol, ketoprofen, seratrodast, sulfamoxole, amlodipme, amodiaquine, anastrozole, atovaquone, chloramphenicol, cyclosporine, cimetidine, clotrimazole cocaine, colchicine, cholecalciferol, cyclizine, dexfenfluramine,
  • dextropropoxyphene dicoumarol, diltiazem, disulfiram, epinephrine, eprosartan, ethanol, felodipine, flecainide, histamine, indinavir, Iopinavir, loratadine, medroxyprogesterone acetate, methazolamide, moclobemide, modaf il, nelfmavir, nifedipine, nilutamide, mlvadipine, olanzapine, phentemune, pioglitazone, praniukast, pravastatin, promethazine, propafenone, quinidine, rutin, saquinavir, selegiline, sulfadimethoxine, sulfamethizole, sulfanilamide, suifapyridine, tegaserod, methimazole, thioridazine,
  • the UDP-glucuronosyltransferase (UGT) enzyme UGT1A1 inhibitor is adenine, propofol, indomethacin, nilotinib, pazopanib, regorafenib, flunitrazepam, erlotinib, sorafenib, enasidenib, pibrentasvir, glecaprevir, rucaparib, ertuglif!ozin, or fostamatinib.
  • the UDP-glucuronosyltransferase (UGT) enzyme UGT1A6 inhibitor is troglitazone.
  • the UGT substrate is diclofenac.
  • SIPi sphingosine 1 -phosphate subtype 1
  • Compound 1 chosen from (i?)-2-(7 ⁇ (4 ⁇ cyc!opentyl-3
  • SI Pi sphingosine 1 -phosphate subtype 1 receptor modulator chosen from R
  • the method further comprises monitoring the patient for signs and symptoms of toxicity and clinical response associated with the substrate of the membrane transporter.
  • the method further comprises reducing the amount of the substrate of the membrane transporter administered to the patient based on the patient’s ability to tolerate one or more exposure -related adverse reactions related to the substrate of the membrane transporter.
  • the method further comprises informing the patient or a medical care worker that co-administration of the SIPi receptor modulator and the substrate of a membrane transporter may result in increased exposure of the substrate of the membrane transporter. In some embodiments, the method further comprises informing the patient or a medical care worker that co-administration of the S lPi receptor modulator and the substrate of the membrane transporter may result in increased risk of one or more exposure-related adverse reactions associated with the substrate of the membrane transporter.
  • monitoring for signs and symptoms of toxicity and clinical response comprises monitoring the serum concentration of the substrate of the membrane transporter.
  • monitoring for signs and symptom s of toxicity and clinical response comprises determining whether the patient experiences one or more exposure-related adverse reaction associated with serum concentration of the substrate of the membrane transporter.
  • monitoring for signs and symptoms of toxicity and clinical response comprises monitoring efficacy of the substrate of the membrane transporter.
  • the membrane transporter is P-glycoprotein (Pgp). In some embodiments, the membrane transporter is BCRP (breast cancer resistance protein). In some embodiments, the membrane transporter is QATP1BI.
  • the membrane transporter is P-glycoprotein.
  • the substrate of the membrane transporter is chosen from digoxin, loperamide, berberine, irinotecan, doxorubicin, vinblastine, paclitaxel, and fexofenadine.
  • the membrane transporter is BCRP.
  • the substrate of the membrane transporter is chosen from mitoxantrone, methotrexate, topotecan, imatinib, irinotecan, statins, sulphate conjugates, and porphyrins.
  • the membrane transporter is OATP1B1.
  • the substrate of the membrane transporter is chosen from bromosulphophthalein, oestrone-3 -sulphate, oestradiol-l7 -glucuronide, statins, repagiimde, valsartan, olmesartan, bilirubin glucuronide, bilirubin, and bile acids.
  • the substrate of the membrane transporter is rifampin.
  • the membrane transporter is OATPIB3. In some embodiments, the substrate of the membrane transporter is rifampin.
  • the dosage form is administered under fasted conditions. In some embodiments, the dosage form is administered under fed conditions.
  • the method is non-gender specific.
  • the individual is also being administered one or more agents independently- chosen from oral corticosteroids and aminosalicylates.
  • the individual is not being administered one or more agents independently chosen from natalizumab, efalizumab, and rituximab.
  • the administration of Compound 1 is not initiated if the individual is being administered one or more agents independently- chosen from natahzumab, efalizumab, and rituximab.
  • the administration of Compound 1 is discontinued if the individual is being administered one or more agents independently chosen from natahzumab, efalizumab, and rituximab.
  • the dose of Compound 1 is reduced if the individual is being administered one or more agents independently chosen from natalizumab, efalizumab, and rituximab.
  • the individual has not been administered a biologic agent.
  • the individual has not been administered two or more biologic agents.
  • the individual has not been administered three or more biologic agents.
  • the individual is not being administered a biologic agent.
  • the individual is not being administered two or more biologic agents.
  • the individual is not being administered three or more biologic agents.
  • the standard dose is administered without titration: and the individual does not experience a severe related adverse event.
  • the therapeutically effective amount is equivalent to about 0 5 to about 5.0 mg of Compound 1 if the individual does not have an active infection. In some embodiments, Compound 1 is not administered to the individual 1 if the individual has an active infection. In some embodiments, the active infection is a serious active infection. In some embodiments, the method further comprises monitoring the individual for an active infection. In some embodiments, the method further comprises discontinuing administration if the individual develops an active infection.
  • the method further comprises monitoring for adverse events during the admini stration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and optionally, interrupting or terminating the administration of Compound I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
  • the treatment further comprises monitoring heart rate during the administration, monitoring pulmonary ' function during the administration, or monitoring liver function during the administration.
  • the treatment further comprises monitoring heart rate during the administration.
  • the treatment further comprises monitoring pulmonary function during the administration.
  • the treatment further comprises monitoring liver function during the administration.
  • the method reduces the incidence and severity of adverse events resulting from the treatment of the sphingosine 1 -phosphate subtype 1 (S lPi) receptor-associated disorder.
  • the adverse event is a serious adverse event.
  • the serious adverse event is selected from leukopenia, constipation, diarrhea, nausea, abdominal pam, neutropenia, vomiting, back pain, and menstrual disorder. In some embodiments, the method results in no serious adverse events.
  • the standard dose is administered without substantially inducing an acute heart rate reduction or heart block in the individual.
  • Compound 1 is administered without causing a reduction of more than 6 bpm in heart rate.
  • Compound 1 is administered without a first-dose effect on heart rate as seen with other SIP receptor modulators. In some embodiments. Compound 1 is administered without a first- dose effect on AV conduction as seen with other SIP receptor modulators.
  • the individual was pre viously administered at least one agent selected from: a TNF antagonist, an integrin antagonist, and an immunosuppressive agent.
  • the individual had an inadequate response with, lost response to, or was intolerant to the at least one agent.
  • the individual had demonstrated, over the previous 3-month period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5- aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists. In some embodiments, the individual had demonstrated, over the previous 6-month period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists.
  • the individual had demonstrated, over the previous 9-month period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists. In some embodiments, the individual had demonstrated, over the previous 1-year period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5 -aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists.
  • the individual had demonstrated, over the previous 2-year period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists. In some embodiments, the individual had demonstrated, over the previous 3-year period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists.
  • the individual had demonstrated, over the previous 4-year period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists. In some embodiments, the individual had demonstrated, over the previous 5 -year period, an inadequate response to, loss of response to, or intolerance of at least one agent selected from oral 5-aminosalicylates, corticosteroids, immunosuppressives, TNFa antagonists, and integrin antagonists. In some embodiments, the standard dose is administered without titration.
  • the individual has fasted prior to being administered the standard dose
  • treating comprises inducing and/or maintaining clinical response; improving endoscopic appearance of the mucosa; and/or inducing and/or maintaining clinical remission.
  • treating comprises inducing and/or maintaining histologic improvement.
  • treating comprises inducing and/or maintaining histologic remission.
  • treating comprises inducing and/or maintaining mucosal healing.
  • the individual prior to the administering the individual has a 3-component Mayo Clinic Score of at least 6.
  • the method results in an improvement of the individual’s 3 -component Mayo Clinic Score. In some embodiments, the method results in an improvement of the individual’s 2- component Mayo Clinic Score. In some embodiments, the method results in an improvement of the individual’s Total Mayo Clinic Score.
  • the treatment results in endoscopic improvement, e.g., improving endoscopic appearance of the mucosa.
  • the treatment results in inducing clinical remission.
  • the treatment results in maintaining clinical remission.
  • the treatment results in inducing and maintaining clinical remission.
  • the treatment results in inducing clinical response.
  • the treatment results in maintaining clinical response.
  • the treatment results in inducing and maintaining clinical response.
  • the treatment reduces a lymphocyte count in the individual by at least 40%. In some embodiments, the treatment reduces a lymphocyte count in the individual by at least 45%, 50%, 55%, 60%, or 65%. In some embodiments of the method of treatment of inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in corticosteroid-free remission.
  • inflammatory bowel disease e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis
  • the treatment results in endoscopic remission.
  • the treatment results in an improvement in rectal bleeding.
  • the treatment results in histologic healing.
  • the treatment results in an improvement in stool frequency.
  • the treatment further comprises monitoring the level of level of fecal calprotectin.
  • the treatment further comprises monitoring the level of level of c-reactive protein (CRP).
  • CRP c-reactive protein
  • treating is reducing a sign and/or symptom of ulcerative colitis. In some embodiments, treating is reducing a sign of ulcerative colitis. In some embodiments, treating is reducing a symptom of ulcerative colitis. In some embodiments, treating is reducing a sign and/or symptom of Crohn’s disease. In some embodiments, treating is reducing a sign of Crohn’s disease. In some embodiments, treating is reducing a symptom of Crohn’s disease.
  • treating is inducing and/or maintaining clinical remission. In some embodiments, treating is inducing and maintaining clinical remission. In some embodiments, treating is inducing and/or maintaining clinical remission and/or clinical response. In some embodiments, treating is inducing and maintaining clinical remission and clinical response. In some embodiments, treating is inducing clinical remission and/or clinical response. In some embodiments, treating is maintaining clinical remission and/or clinical response. In some embodiments, treating is inducing clinical remission and clinical response. In some embodiments, treating is maintaining clinical remission and clinical response. In some embodiments, treating is inducing and/or maintaining clinical remission and/or mucosal healing.
  • treating is inducing and maintaining clinical remission and mucosal healing. In some embodiments, treating is inducing and maintaining mucosal healing. In some embodiments, treating is inducing and maintaining clinical remission. In some embodiments, treating is inducing ciinical remission. In some embodiments, treating is inducing mucosal healing. In some embodiments, treating is maintaining clinical remission. In some embodiments, treating is maintaining mucosal healing. In some embodiments, treating is achieving and/or sustaining clinical remission in induction responders. In some embodiments, treating is achieving and sustaining clinical remission in induction responders. In some embodiments, treating is achieving clinical remission in induction responders.
  • treating is sustaining clinical remission in induction responders. In some embodiments, treating is inducing and/or maintaining clinical response. In some embodiments, treating is inducing and maintaining clinical response. In some embodiments, treating is inducing clinical response. In some embodiments, treating is maintaining clinical response hi some embodiments, treating is inducing endoscopic improvement i some embodiments, treating is maintaining endoscopic improvement. In some embodiments, treating is achieved endoscopic improvement. In some embodiments, treating is improving endoscopic remission. In some embodiments, treating is maintaining endoscopic remission. In some embodiments, treating is inducing histologic healing. In some embodiments, treating is maintaining histologic healing. In some embodiments, treating is improving stool frequency. In some embodiments, treating is maintaining improvement in stool frequency.
  • treating is improving endoscopic appearance of the mucosa. In some embodiments, treating is maintaining endoscopic improvement of the mucosa. In some embodiments, treating is improving endoscopic appearance of the mucosa during induction hi some embodiments, treating eliminates the need for corticosteroid rise. In some embodiments, treating allows for reduced corticosteroid use. In some embodiments, treating allows for the use of a lower dose of a corticosteroid. In some embodiments, treating is achieving corticosteroid-free remission. In some embodiments, treating is sustaining corticosteroid-free remission. In some embodiments, treating is improving rectal bleeding. In some embodiments, treating is maintaining improvement in rectal bleeding in some embodiments, treating is improving endoscopic subscore. In some embodiments, treating is maintaining improvement in endoscopic subscore.
  • ulcerative colitis has been diagnosed using a 2-component Mayo Clinic Score. For example, in some embodiments, ulcerative colitis has been diagnosed using a score ranging from 0 to 9 for rectal bleeding and endoscopic findings. In some embodiments, ulcerative colitis has been diagnosed using a 3-component Mayo Clinic Score. For example, in some embodiments, ulcerative colitis has been diagnosed using a score ranging from 0 to 9 for stool frequency, rectal bleeding, and endoscopic findings. In some embodiments, ulcerative colitis has been diagnosed using a Total Mayo Score. For example, in some embodiments, ulcerative colitis has been diagnosed using a score ranging from 0 to 12 for stool frequency, rectal bleeding, endoscopic findings, and Physicians Global Assessment.
  • improvement in ulcerative colitis is measured using a 2-component Mayo Clinic Score. In some embodiments, improvement in ulcerative colitis is measured using a 3 -component Mayo Clinic Score. In some embodiments, improvement in ulcerative colitis is measured using a Total Mayo Score. In some embodiments, improvement in ulcerative colitis is measured by clinical remission in some embodiments, improvement in ulcerative colitis is measured by lymphocyte reduction. In some embodiments, improvement in ulcerative colitis is measured by endoscopic improvement. In some embodiments, improvement in ulcerative colitis is measured by 6-point Mayo Score. For example, in some embodiments, improvement in ulcerative colitis is measured by stool frequency and rectal bleeding. In some embodiments, improvement in ulcerative colitis is statistically significant.
  • Compound 1 is not recommended in an individual with active, severe infection. In some embodiments, Compound 1 is not recommended in an individual with an active infection. In some embodiments, Compound 1 is not recommended in an individual with a severe infection. In some embodim nts, Compound 1 is not recommended in an individual with an active, severe infection until the infection is controlled. In some embodiments, Compound 1 is not recommended in an individual with an active infection until the infection is controlled. In some embodiments, Compound 1 is not recommended in an individual with a severe infection until the infection is controlled. In some embodiments, administration of Compound 1 is not started during an active infection. In some embodiments, an individual is monitored for infection. In some embodiments, administration of
  • Compound 1 is stopped if an individual develops an infection. In some embodiments, administration of Compound 1 is stopped if infection becomes serious. In some embodiments, administration of Compound 1 is discontinued if an individual develops an infection. In some embodiments, Compound 1 is not administered to an individual with an infection. In some embodiments, Compound 1 is not administered during an active infection. In some embodiments, administration of Compound 1 is not started during active infection; an individual is monitored if an infection develops during administration; and
  • an infection is mild. In some embodiments, an infection is moderate. In some embodiments, an infection is severe. In some embodiments, an infection is serious. In some embodiments, an infection is a serious adverse event. In some embodiments, an infection is a respiratory infection.
  • Compound 1 is administered without causing a severe adverse event. In some embodiments, Compound 1 is administered without causing a severe adverse event related to heart rate. In some embodiments, Compound 1 is administered without causing a severe adverse event related to heart rate change. In some embodiments. Compound 1 is administered without causing a severe adverse event related to elevated heart rate hr some embodiments, Compound I is administered without causing a severe adverse event related to bradycardia. In some embodiments, Compound 1 is administered without causing a severe adverse event related to AV block. In some embodiments, Compound 1 is administered without causing a severe adverse event related to AV conduction. In some embodiments, Compound 1 is administered without causing bradycardia.
  • Compound 1 is administered without causing AV block. In some embodiments, Compound 1 is administered without causing more than mild decrease heart rate on first day of treatment (for example, >10 bpm). In some embodiments, Compound 1 is administered without a first-dose effect seen with other SIP receptor modulators. In some embodiments. Compound 1 is administered without a first-dose cardiovascular effect seen with other SIP receptor modulators. In some embodiments, Compound 1 is administered without symptomatic changes in heart rate. In some embodiments, Compound 1 is administered without symptomatic changes in heart rhythm. In some embodiments, Compound 1 is administered without requiring titration to avoid first-dose effect seen with other SIP receptor modulators.
  • Compound 1 is administered without increasing a liver function test (LFT). In some embodiments, Compound 1 is administered without causing an elevated LFT. In some embodiments. Compound 1 is administered without increasing ALT. In some embodiments, Compound 1 is administered without increasing AST. In some embodiments. Compound 1 is administered without increasing ALT >3X ULN. In some embodiments. Compound 1 is administered without increasing ALT >2.5X ULN. In some embodiments, Compound I is administered without increasing ALT >2X ULN. hr some embodiments. Compound 1 is administered without increasing ALT >1.5X ULN. In some embodiments, Compound 1 is administered without increasing AST >3X ULN.
  • LFT liver function test
  • Compound 1 is administered without increasing AST >2.5X ULN. In some embodiments, Compound 1 is administered without increasing AST >2X ULN. In some embodiments, Compound 1 is administered without increasing AST >!.5X ULN. In some embodiments, Compound 1 is administered without increasing bilirubin. In some embodiments, Compound 1 is administered without increasing bilirubin >3X ULN. In some embodiments, Compound 1 is administere without increasing bilirubin >2.5X ULN. In some embodiments, Compound 1 is administered without increasing bilirubin >2X ULN. In some embodiments, Compound 1 is administered without increasing bilirubin >1 5X ULN .
  • Compound 1 is administered without increasing gamma-glutamyl transferase (GGT). In some embodiments. Compound 1 is administered without increasing GGT >3X ULN. In some embodiments, Compound 1 is administered without increasing GGT >2.5X ULN. In some embodiments, Compound 1 is administered without increasing GGT >2X ULN. In some embodiments, Compound 1 is administered without increasing GGT >!.5X ULN.
  • GGT gamma-glutamyl transferase
  • Compound 1 is administered without causing an abnonnality in a pulmonary function test. In some embodiments, Compound 1 is administered without causing macular edema.
  • the individual has had an inadequate response with, lost response to, been intolerant to, or demonstrated dependence on another agent for the treatment of an inflammatory bowel disease. In some embodiments, the individual has had an inadequate response with the other agent for the treatment of an inflammatory bowel disease. In some embodiments, the individual has lost response to another agent for the treatment of an inflammatory bowel disease. In some embodiments, the individual was intolerant to another agent for the treatment of an inflammatory bowel disease. In some embodiments, the individual requires continuous steroid therapy. In some embodiments, the other agent is at least one agent selected from; a tumor necrosis tumor necrosis factor (TNF) antagonist, a corticosteroid, an integrin antagonist, and immunosuppressive agent, and an aminosalicylate.
  • TNF tumor necrosis tumor necrosis factor
  • the individual has had an inadequate response with, lost response to, or been intolerant to a conventional therapy. In some embodiments, the individual has had an inadequate response to conventional therapy. In some embodiments, the individual has lost response to conventional therapy. In some embodiments, the individual has been intolerant to conventional therapy. In some embodiments, the conventional therapy is selected from: at least one agent selected from: a tumor necrosis tumor necrosis factor (TNF) antagonist, a corticosteroid, an integrin antagonist, and immunosuppressive agent, and an aminosalicylate.
  • TNF tumor necrosis tumor necrosis factor
  • the individual was previously administered a corticosteroid and/or an aminosalicylate. In some embodiments, the individual was previously administered a tumor necrosis tumor necrosis factor (TNF) antagonist, an integrin antagonist, and/or an immunosuppressive agent.
  • TNF tumor necrosis tumor necrosis factor
  • the corticosteroid is an oral corticosteroid.
  • the TNF antagonist is a TNF-a blocker.
  • the aminosalicylate is a 5-aminosaiicylate.
  • the integrin antagonist is referred to as an integrin receptor antagonist.
  • the TNF antagonist is referred to as a TNF blocker.
  • the TNF blocker is referred to as a TNF blocker.
  • immunosuppressive agent is referred to as an immunomodulator.
  • prior conventional therapy is referred to as prior treatment.
  • the indi vidual is not administered a therapeutic dose of a thiopurine .
  • the individual is not administered a therapeutic dose of azathioprine.
  • the individual is not administered a therapeutic dose of 6-mercaptopurine.
  • the individual is not administered a therapeutic dose of thioguanine (also referred to as tioguamne or 6-thioguanine).
  • the inhibitor is a moderate inhibitor. In some embodiments, the inhibitor is a strong inhibitor. In some embodiments, the inducer is a moderate inducer. In some embodiments, the inducer is a strong inducer.
  • caution is used when Compound 1 is co-administered with a CYP substrate. In some embodiments, caution is used when Compound 1 is co-administered with a UGT substrate. In some embodiments, caution is used when Compound 1 is co-administered with an OAT substrate. In some embodiments, caution is used when Compound 1 is co-administered with strong inhibitors. In some embodiments, the strong inhibitor is a strong CYP inhibitor. In some embodiments, the strong inhibitor is a CYP2C8. In some embodiments, caution is used when Compound 1 is co-administered with moderate inhibitors. In some embodiments, the moderate inhibitor is a moderate CYP inhibitor.
  • the moderate inhibitor is a CYP2C9 inhibitor. In some embodiments, caution is used when Compound 1 is co-administered with strong inducers. In some embodiments, the strong inhibitor is a strong CYP inducer. In some embodiments, caution is used when Compound 1 is co-administered with moderate inducers. In some embodiments, the moderate inducer is a moderate CYP inhibitor. In some embodiments, the moderate inducer is a CYP2C8 inducer. In some embodiments, the moderate inducer is a CYP2C9 inducer.
  • the dose of Compound 1 is limited when used with a CYP substrate. In some embodiments, the dose of Compound 1 is limited when used a UGT substrate. In some
  • the dose of Compound 1 is limited when used with an OAT substrate. In some embodiments, the dose of Compound 1 is limited when used with an OAT substrate.
  • the dose of Compound 1 is limited when used with strong inhibitors. In some embodiments, the dose of Compound 1 is limited to, or is limited to about, does not exceed, or does not exceed about,
  • Compound 1 is administered at the lowest dose when used with a strong inhibitor hi some embodiments, the dose of Compound 1 is limited when used with moderate inhibitors. In some embodiments, Compound 1 is administered at the lowest dose when used with a moderate inhibitor. In some embodiments, the lowest dose is the lowest efficacious dose. In some embodiments, the lowest dose is the lowest marketed dose. In some embodiments, the lowest dose is the lowest marketed dose in the United States.
  • the lowest dose of Compound 1 is, or is about, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7. 0.75, 0 8, 0 9, 1.0., 1 .1., 1 2, 1 3, 1 4, 1 5, 1 6, 1 7, 1 75, 1.8, 1 9, or 2.0 mg.
  • the dose of a co-administered compound is limited when used with Compound 1.
  • the co-administered compound is a CYP substrate.
  • the co-administered compound is a UGT substrate.
  • the dose of a co administered compound is an OAT substrate.
  • the co-administered compound is a strong inducer.
  • the co-adrninistered compound is a strong inhibitor.
  • the co-administered compound is a moderate inducer.
  • the co administered compound is a moderate inhibitor.
  • the co-administered compound is administered at the lowest dose.
  • the lowest dose is the lowest efficacious dose.
  • the lowest dose is the lowest marketed dose.
  • the lowest dose is the lowest marketed dose in the United States.
  • Compound 1 is not used with a CYP substrate. In some embodiments, Compound 1 is not used with a UGT substrate. I some embodiments. Compound 1 is not used with an OAT substrate. In some embodiments. Compound 1 is not used with strong inducers. In some embodiments, Compound 1 is not used with moderate inducers. In some embodiments. Compound 1 is not used with strong inhibitors hi some embodiments, Compound I is not used with moderate inhibitors. In some embodiments, concomitant use of Compound 1 is not recommended with a CYP substrate. In some embodiments, concomitant use of Compound I is not recommended with a UGT substrate. In some embodiments, concomitant use of Compound 1 is not recommended with an OAT substrate.
  • concomitant use of Compound 1 is not recommended with strong inducers. In some embodiments, concomitant use of Compound 1 is not recommended with moderate inducers. In some embodiments, concomitant use of Compound 1 is not recommended with strong inhibitors. In some embodiments, concomitant use of Compound 1 is not recommended with moderate inhibitors. In some embodiments, concomitant use of Compound 1 is not recommended with a CYP2C8 inhibitor. In some embodiments, concomitant use of Compound 1 is not recommended with a CYP2C8 inducer. In some embodiments, concomitant use of Compound 1 is not recommended with a CYP2C9 inhibitor. In some embodiments, concomitant use of Compound 1 is not recommended with a CYP2C8 inducer.
  • Some embodiments provide a method of safely treating an individual with ( R)-2 ⁇ (7-(4-cyclopenty! ⁇ 3-(trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[6]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
  • Some embodiments provide a method of safely administering (i?)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-l,2,3,4-tetrahydrocyclopenta[Z>]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
  • Some embodiments provide a method of administering a daily dose of Compound 1 when an individual is concomitantly receiving a CYP substrate, OAT substrate, or UGT substrate.
  • the daily dose of Compound 1 is nor more than, or no more than about, 0.25, 0.3, 0 4, 0.5, 0.6, 0.7. 0.75, 0.8, 0.9, 1.0., 1.1., 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.4, 2.5, 2.6, 2.7, 2.75, 2.8, 2.9, or 3.0 mg.
  • the daily dose of Compound 1 is less than, or less than about, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7. 0.75, 0.8, 0.9, 1.0., 1.1., 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, 1.9, 2.0, 2.1, 2.2, 2.25, 2.3, 2.4, 2.5, 2.6, 2.7, 2.75, 2.8, 2.9, or 3.0 mg.
  • the CYP substrate is a CYP2C8 substrate.
  • the CYP substrate is a CYP2C9 substrate.
  • the UGT substrate is a UGT1A1 substrate.
  • the UGT substrate is a UGT1A4 substrate.
  • the UGT substrate is a UGT1A6 substrate.
  • the UGT substrate is a UGT1A7 substrate.
  • the OAT substrate is an OATP1BI substrate.
  • the OAT substrate is an OATP1B3 substrate.
  • the OAT substrate is an OAT1 substrate.
  • the OAT substrate is an OAT3 substrate.
  • the CYP2C8 inhibitor, CYP2C9 inhibitor, CYP2C8 inducer, or CYP2C9 inducer is fluconazole.
  • the CYP2C8 inhibitor, CYP2C9 inhibitor, CYP2C8 inducer, or CYP2C9 ducer is gemfibrozil
  • the CYP2C8 inhibitor, CYP2C9 inhibitor, CYP2C8 inducer, or CYP2C9 inducer is rifampin.
  • the substrate of OATP1B1 is rifampin.
  • the substrate of OATP1B3 is rifampin.
  • the co-administered compound is a CYP2C8 inhibitor.
  • the co-administered compound is a CYP2C8 inducer.
  • the co-administered compound is a CYP2C9 inhibitor.
  • the co-administered compound is a CYP2C9 inducer.
  • the co-administered compound is fluconazole.
  • the co-administered compound is gemfibrozil.
  • the co-administered compound is rifampin.
  • less than the amount that would be administered to a patient who is not also being administered a CYP substrate, OAT substrate, UGT substrate, CYP2C8 inhibitor, CYP2C9 inhibitor, CYP2C8 inducer, CYP2C9 inducer, UGT1A1 inhibitor, or UGT1A6 inhibitor is about, at least, or at least about, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 778, 79, 80, 81 , 82, 83,
  • CYP substrate OAT substrate, UGT substrate, CYP2C8 inhibitor, CYP2C9 inhibitor
  • CYP2C8 inducer
  • CYP2C9 inducer
  • UGT1A1 inhibitor or UGT1A6 inhibitor.
  • less than the amount that would be administered to a patient who is not also being administered a CYP substrate, OAT substrate, UGT substrate, CYP2C8 inhibitor, CYP2C9 inhibitor, CYP2C8 inducer, CYP2C9 inducer, UGT1A1 inhibitor, or UGT1A6 inhibitor is about, at least, or at least about, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8, 0.9, 1.0, 1.1, 1.2, 1.25, 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, 1.9, or 2.0 mg less than the amount that would be administered to a patient who is not also being administered a CYP substrate, OAT substrate, UGT substrate, CYP2C8 inhibitor, CYP2C9 inhibitor,
  • CYP2C8 inducer
  • CYP2C9 inducer
  • UGT1A1 inhibitor or UGT1A6 inhibitor.
  • Some embodiments provide a method of safely administering a sphingosine 1 -phosphate subtype 1 (SIP ) receptor modulator chosen from (i?)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-l,2,3,4- tetrahydrocyclopenta[6]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, to a patient in need thereof wherein the patient is also being administered a cytochrome P450 (CYP) inhibitor, CYP inducer, organic anion transporter (OAT) substrate, UDP- glucuronosyltransferase (UGT) enzyme inhibitor, or UDP-glucuronosy!transferase (UGT) enzyme inhibitor, comprising administering to the patient a daily dose of less than 2 mg of the SIP modulator.
  • SIP sphingosine 1 -phosphate subtype 1
  • the daily dose of the SIP ⁇ , modulator is selected from: 1.0, 1.25, 1.5, and 1.75 mg of the SI Pi modulator.
  • lymphopenia also referred to as peripheral lymphocyte lowering (PLL); Hale et ai, Bioorg. Med. Chem. Lett. , 14:3351-3355, 2004. This is attended by clinically useful immunosuppression by virtue of sequestering T- and B-cells in secondary lymphoid tissue (lymph nodes and Peycr’s patches) and thus apart from sites of inflammation and organ grafts (Rosen et ai, Immunol. Rev. , 195: 160-177,
  • lymphocyte sequestration for example in lymph nodes, is thought to be a consequence of concurrent agonist-driven functional antagonism of the S 1 Pi receptor on T-cells (whereby the ability of SIP to mobilize T-cell egress from lymph nodes is reduced) and persistent agonism of the SIPi receptor on lymph node endothelium (such that barrier function opposing transmigration of lymphocytes is increased) (Matloubian et al, Nature, 427:355-360, 2004; Baumruker et al. Expert Opin. Investig. Drugs, 16:283-289, 2007).
  • agonism of the S IP receptor alone is sufficient to achieve lymphocyte sequestration (Sauna et al. , J. Biol. Chem. , 279: 13839-13848, 2004) and that this occurs without impairment of immune responses to systemic infection (Brinkmann et ai, Transplantation, 72:764-769, 2001; Brinkmann et ai., Transplant: Proa, 33:530-531, 2001)
  • That agonism of endothelial SIPi receptors has a broader role in promoting vascular integrity is supported by work implicating the SIPi receptor in capillary integrity in mouse skin and lung (Sauna et al, Nat. Chem. Biol, 2:434-441, 2006).
  • Vascular integrity can be compromised by inflammatory processes, for example as may derive from sepsis, major trauma and surgery so as to lead to acute lung injury or respiratory distress syndrome (Johan Groeneveld, Vascul. Pharmacol , 39:247-256, 2003).
  • An exemplary SIP receptor agonist having agonist activity on the SlPi receptor is FTY720 (fmgoiimod), an immunosuppressive agent that has undergone clinical trials (Martini et al, Expert Opin Investig. Drugs, 16:505-518, 2007) and was recently approved by the FDA for the treatment of individuals with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
  • FTY720 acts as a prodrug which is phosphorylated in vivo; the phosphorylated derivative is an agonist for S IPi, SIP3, S IP4 and SIP5 receptors (but not the Sllti receptor) (Chiba, Pharmacology & Therapeutic , 108:308-319, 2005). FTY720 has been shown to rapidly 7 and reversibly induce lymphopenia; Hale et al. , Bioorg. Med. Chem. Lett., 14:3351-3355, 2004).
  • FTY720 elicited an adverse event (i.e., transient asymptomatic bradycardia) which may be due to its agonism of the S1P 3 receptor (Budde et al., J Am. Soc. Nephrol , 13: 1073-1083, 2002; Sauna et al , J. Biol. Chern., 279: 13839-13848, 2004; Ogawa et al, BBRC, 361 :621-628, 2007).
  • an adverse event i.e., transient asymptomatic bradycardia
  • FTY720 has been reported to have therapeutic efficacy in at least: a rat model for autoimmune myocarditis and a mouse model for acute viral myocarditis (Kiyabayashi etal., J. Cardiovasc. Pharmacol. , 35:410-416, 2000; Miyamoto et al., J. Am. Coll. Cardiol, 37: 1713-1718, 2001 ); mouse models for inflammator bowel disease including colitis (Mizushima et al , Inflamm. Bowel Dis. , 10: 182-192, 2004; Deguchi etal. Oncology Reports, 16:699-703, 2006; Fuji! et al., Am. J. Physiol Gastrointest.
  • mice model for asthma suggested to be primarily through the SI P receptor on the basis of work using the SlPi receptor agonist SEW2871 (idzko et al. , J Clin. Invest., 116:2935- 2944, 2006); a mouse model for airway inflammation and induction of bronchial hyperresponsiveness (Sawicka et al, J. Immunol, 171 ;6206-6214, 2003); a mouse model for atopic dermatitis (Kohno etal, Biol Pharm. Bull, 27: 1392-1396, 2004); a mouse model for ischemia-reperfusion injury (Kaudel et al. Transplant.
  • KRP-203 an SIP receptor agonist having agonist activity on the SlPi receptor, has been reported to have therapeutic efficacy in a rat model for autoimmune myocarditis (Ogawa et al , BBRC, 361:621-628, 2007).
  • S 1 Pi receptor agonist SEW2871 it has been shown that agonism of endothelial SIP receptors prevents proinf!ammatory monocyte/endothelial interactions in type I diabetic vascular endothelium (Whetzel et al, Circ.
  • FTY720 has been reported to have therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE) in rats and mice, a model for human multiple sclerosis (Brinkmann et al. , J. Biol. Chem . , 277:21453-21457, 2002; Fujino et al., J Pharmacol Exp. Ther. , 305: 70-77, 2003; Webb et al. , J. Neuroimmunol, 153: 108-121, 2004; Rausch et al, J Magn. Reson Imaging, 20: 16-24, 2004; Kataoka et al , Cellular & Molecular Immunology , 2:439-448, 2005; Brinkmann et al.
  • EAE experimental autoimmune encephalomyelitis
  • FTY720 has been found to have therapeutic efficacy for multiple sclerosis in clinical trials. In Phase 11 clinical trials for relapsing-remitting multiple sclerosis, FTY720 was found to reduce the number of lesions detected by magnetic resonance imaging (MRI) and clinical disease activity in individuals with multiple sclerosis (Kappos et al , N Engl. J. Med. , 355: 1124- 1140, 2006; Martini et al, Expert Opin.
  • MRI magnetic resonance imaging
  • FTY720 has also been reported to have anti-viral activity. Specific data has been presented in the lymphocytic choriomeningitis virus (LCMV) mouse model, wherein the mice were infected with either the Armstrong or the clone 13 strain of LCMV (Premenko-Lanier et al. Nature, 454, 894, 2008).
  • LCMV lymphocytic choriomeningitis virus
  • FTY720 has been reported to impair migration of dendritic cells infected with Francisella tularensis to the mediastinal lymph node, thereby reducing the bacterial colonization of it.
  • Francisella tularensis is associated with tularemia, ulcerogiandular infection, respiratory infection and a typhotdai disease (E. Bar-Haim et al , PLoS Pathogens, 4(11): e 100021 1 , published 21 November 2008;
  • Agonism of tire SIPi receptor has been implicated in enhancement of survival of oligodendrocyte progenitor cells. Survival of oligodendrocyte progenitor cells is a required component of the remyelination process. Remyelination of multiple sclerosis lesions is considered to promote recovery from clinical relapses (Miron et aI., Ahh. Neurol. , 63:61-71, 2008; Coelho et al., J. Pharmacol. Exp. Ther., 323:626-635, 2007; Dev et al. , Pharmacology and Therapeutics, 117:77-93, 2008).
  • PDGF platelet-derived growth factor
  • Agonism of the SIPi receptor has also been reported to mediate migration of neural stem cells toward injured areas of the central nervous system (CNS), including in a rat model of spinal cord injury (Kimura etal.. Stem Cells, 25: 1 15-124, 2007).
  • Agonism of the SIPi receptor has been implicated in the inhibition of keratinocyte proliferation (Sauer etal., J. Biol. Ghent., 279:38471-38479, 2004), consistent with reports that SIP inhibits keratinocyte proliferation (Kim et al, Cell Signal 16:89-95, 2004).
  • the hyperproliferation of keratinoeytes at the entrance to the hair follicle, which can then become blocked, and an associated inflammation are significant pathogenetic factors of acne (Koreck et al., Dermatology, 206:96-105, 2003; Webster, Cutis, 76(2
  • FTY720 has been reported to have therapeutic efficacy in inhibiting pathologic angiogenesis, such as that as may occur in tumor development. Inhibition of angiogenesis by FTY720 is thought to involve agonism of the SI Pi receptor (Oo et al., J. Biol. Chem., 282;9082-9089, 2007; Schmid et al., J. Cell Biochem., 101:259-270, 2007). FTY720 has been reported to have therapeutic efficacy for inhibiting primary and metastatic tumor growth in a mouse model of melanoma (LaMontagne et al. , Cancer Res. , 66:221 -231, 2006) FTY720 has been reported to have therapeutic efficacy in a mouse model for metastatic hepatocellular carcinoma (Lee et al, Clin. Cancer Res., 11:84588466, 2005).
  • Cyclosporin A and FK506 are drugs used to prevent rejection of transplanted organs. Although they are effective in delaying or suppressing transplant rejection, classical immunosuppressants such as cyclosporin A and FK506 are known to cause several undesirable side effects including nephrotoxicity, neurotoxicity, b-cell toxicity and gastrointestinal discomfort. There is an unmet need in organ transplantation for an immunosuppressant without these side effects which is effective as a monotherapy or in combination with a classical immunosuppressant for inhibiting migration of, e.g., alloantigen-reactive T-ceils to the grafted tissue, thereby prolonging graft survival.
  • classical immunosuppressants such as cyclosporin A and FK506 are known to cause several undesirable side effects including nephrotoxicity, neurotoxicity, b-cell toxicity and gastrointestinal discomfort.
  • FTY720 has been shown to have therapeutic efficacy in transplant rejection both as a monotherapy and in synergistic combination with a classical immunosuppressant, including cyclosporin A, FK506, and RAD (an mTOR inhibitor). It has been shown that, unlike the classical immunosuppressants cyclosporin A, FK506 and RAD, FTY72Q has efficacy for prolonging graft survival without inducing general
  • FTY720 has been reported to have therapeutic efficacy for prolonging allograft survival in a rat cardiac allograft model (Suzuki et at , Transpl. Immunol. , 4:252-255, 1996). FTY720 has been reported to act synergistically with cyclosporin A to prolong rat skin allograft survival (Yanagawa et al. , J Immunol , 160:5493-5499, 1998), to act
  • KRP-203 an SIP receptor agonist has been reported to have therapeutic efficacy for prolonging allograft survival in a rat skin allograft model and both as monotherapy and in synergistic combination with cyclosporin A in a rat cardiac allograft model (Shimizu et at , Circulation, 1 1 1 : 222-229, 2005). KRP-203 also has been reported to have therapeutic efficacy in combination with mycophenolate mofetil (MMF; a prodrug for which the active metabolite is
  • FTY720 has been reported to act synergistically with cyclosporin A to prolong small bowel allograft survival (Sakagawa et al , Transpl. Immunol , 13: 161-168, 2004).
  • FTY72G has been reported to have therapeutic efficacy in a mouse islet graft model (Fu et al , Transplantation, 73: 1425-1430, 2002; Liu et al , Microsurgery , 27:300-304; 2007) and in a study using human islet cells to evidence no detrimental effects on human islet function (Truong et al. , American Journal of Transplantation, 7:2031-2038, 2007).
  • FTY720 has been reported to reduce the nociceptive behavior in the spared nerve injury ' model for neuropathic pain which does not depend on prostaglandin synthesis (O. Costu et at, Journal of Cellular and Molecular Medicine 12(3), 995-1004, 2008).
  • the present invention encompasses compounds which are agonists of the SlPs receptor having selectivity over the SIP 3 receptor.
  • Sanna et al. reported that sustained bradycardia was induced by nonselective SIP receptor immunosuppressive agonists in wild-type mice but was abolished in SIP 3 -/- mice whereas an SlPi- selective agonist did not produce bradycardia.
  • SIP 3 receptor, and not the SIP ⁇ , receptor was responsible for bradycardia (Sanna et al., J. Biol. Chem., 279: 13839-13848, 2004).
  • an SIPi receptor agonist selective over at least the SIP3 receptor has advantages over current therapies by virtue of an enhanced therapeutic window, allowing better tolerability with higher dosing and thus improving efficacy as therapy.
  • the present invention encompasses Compound 1 (and pharmaceutically acceptable salts, hydrates, and solvates thereof) which is an agonist of the SIPi receptor and has exhibited no or substantially no bradycardia in male Sprague-Dawley® rats (see WQ2010/011316, Example 9).
  • a phase 1 study with Compound 1 was conducted with single dosing at 0.1 mg, 0.35 mg, 1 mg, 3 mg, and 5 mg.
  • Compound 1 was administered as the L-arginine salt.
  • Lower doses of 0.1 mg through 3 mg were well tolerated by subjects with only minor adverse events reported, the most common of which were headache and contact dermatitis.
  • a dose -dependent reduction heart rate - was seen in all doses >0.35 mg, however, no adverse events related to bradycardia were reported at doses lower than the 5 mg dose.
  • Dose limiting adverse events were observed at the dose of 5 mg, with 3 (50%) subjects experiencing 4 AEs of bradycardia with first or second degree atrioventricular (AY) block, which resulted in discontinuation of dose escalation.
  • the maximum tolerated dose in the study was 3 mg. There were no deaths or serious adverse events in the study.
  • peripheral blood lymphocyte counts were reduced by 2-4 hours after dosing, reaching a nadir by hour 8 which persisted for 24 hours with recover ) 7 to baseline over the next 4 days. PBL counts were reduced by -40% and -55% at tire 3 mg and 5 rng dose levels.
  • SIP receptor agonists are useful to treat or prevent conditions where suppression of the immune system or agonism of the SI Pi receptor is in order, such as diseases and disorders mediated by
  • lymphocytes transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders, and conditions that have an underlying defect in vascular integrity or that relate to angiogenesis such as may be pathologic.
  • the present invention encompasses compounds which are agonists of the SIPi receptor having good overall physical properties and biological activities and having an effectiveness that is substantially at least that of prior compounds with activity at the SIP receptor
  • S IP receptor agonists are useful for treating or preventing conditions where suppression of the immune system or agonism of the SIPi receptor is in order, such as diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions that have an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).
  • diseases and disorders mediated by lymphocytes such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).
  • Such conditions where suppression of the immune system or agonism of the SlPi receptor is in order include diseases and disorders mediated by lymphocytes; conditions that have an underlying defect in vascular integrity; autoimmune diseases and disorders;
  • inflammatory diseases and disorders e.g., acute and chronic inflammatory conditions); acute or chronic rejection of cells; tissue or solid organ grafts; arthritis, including psoriatic arthritis, and rheumatoid arthritis; diabetes, including type ⁇ diabetes; demyelinating disease, including multiple sclerosis; ischemia- reperfusion injury ' , including renal and cardiac ischemia-reperfusion injury'; inflammatory ' skin disease, including psoriasis, atopic dermatitis, and acne; hyperproliferative skin disease, including acne;
  • erythematosus erythematosus
  • asthma uveitis
  • myocarditis allergy
  • atherosclerosis brain inflammation, including Alzheimer's disease, and brain inflammatory reaction following traumatic brain injury'; ankylosing spondylitis
  • central nervous system disease including spinal cord injury', or cerebral infarction
  • pathologic angiogenesis including as may occur m primary and metastatic tumor growth
  • rheumatoid arthritis including as may occur m primary and metastatic tumor growth.
  • SIPi receptor agonists are useful for treating microbial infections, and viral infections or diseases.
  • the sphingosine 1-phosphate subtype 1 (SIP i) receptor-associated disorder is selected from: a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary ' cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury and acne.
  • the SI Pi receptor-associated disorder is a disease or disorder mediated by lymphocytes.
  • the SIPi receptor-associated disorder is an autoimmune disease or disorder.
  • the SIPs receptor-associated disorder is an inflammatory disease or disorder.
  • the SiPi receptor-associated disorder is ankylosing spondylitis.
  • the SI Pi receptor-associated disorder is biliary cirrhosis.
  • the SI P ⁇ , receptor-associated disorder is primary biliary ' cholangitis.
  • the SI Pi receptor-associated disorder is cancer.
  • the SiP receptor-associated disorder is psoriasis.
  • the SIPs receptor-associated disorder is erythema nodosum.
  • the SIPs receptor-associated disorder is pyoderma gangrenosum.
  • the SIP ⁇ receptor-associated disorder is psoriatic arthritis.
  • the SlPi receptor-associated disorder is rheumatoid arthritis.
  • the SiPi receptor-associated disorder is Crohn’s disease.
  • the SI P ⁇ , receptor-associated disorder is transplant rejection .
  • the SI Pi receptor-associated disorder is multiple sclerosis.
  • the SIPs receptor-associated disorder is systemic lupus erythematosus.
  • the SIPs receptor-associated disorder is inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • the SIPs receptor-associated disorder is an active skin extra-intestinal manifestation of inflammatory ' ⁇ bowel disease. In some embodiments, the S IPs receptor-associated disorder is £in active skin extra-intestinal manifestation of ulcerative colitis. In some embodiments, the active skin extra-intestinal manifestation is psoriasis hi some embodiments, the active skin extra-intestinal manifestation is erythema nodosum. In some embodiments, the active skin extra-intestinal manifestation is pyoderma gangrenosum.
  • the SIPs receptor-associated disorder is ulcerative colitis. In some embodiments, the SiPi receptor-associated disorder is moderately to severely active ulcerative colitis hi some embodiments, the SlPi receptor-associated disorder is moderately active ulcerative colitis. In some embodiments, the SI P receptor-associated disorder is severely active ulcerative colitis. In some embodiments, the SlPi receptor-associated disorder is mildly to moderately active ulcerative colitis. In some embodiments, the SlPi receptor-associated disorder is mildly active ulcerative colitis.
  • the Sl Pi receptor-associated disorder is type I diabetes.
  • the SI P ⁇ , receptor-associated disorder is hypertensive nephropathy.
  • the SI Pi receptor-associated disorder is glomerulosclerosis. In some embodiments, the SI PI receptor-associated disorder is myocardial ischemia-reperfusion injury.
  • the SIPi receptor-associated disorder is acne.
  • the S!Ps receptor-associated disorder is autoimmune hepatitis.
  • the standard dose is in an amount equivalent to 1 mg of Compound 1.
  • the standard dose is in an amount equivalent to 2 mg of Compound 1
  • the standard dose is in an amount equivalent to 3 mg of Compound 1.
  • the standard dose of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is administered once daily to the individual.
  • the Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is administered orally.
  • the Compound 1 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as a capsule or tablet suitable for oral administration.
  • the Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is selected from: Compound 1 ; a calcium salt of Compound 1 ; and an L-arginine salt of Compound 1.
  • the Compound 1 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof is an L-arginine salt of Compound 1
  • the pharmaceutically acceptable salt, hydrate, or solvate thereof is an anhydrous, non-solvated crystalline form of an L-arginine salt of Compound 1.
  • the Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is an anhydrous, non-solvated crystalline form of Compound 1.
  • the individual also is administered a therapeutic dose of an oral 5 -ASA compound hi some embodiments, the individual also is administered a stable dose of an oral 5-ASA compound.
  • the individual also is administered a therapeutic dose of an oral corticosteroid therapy. In some embodiments, the individual also is administered a stable dose of an oral corticosteroid therapy.
  • the corticosteroid is prednisone, e.g., prednisone at a dose ⁇ 10 tng/day or 20 tng/day, or an equivalent steroid. In some embodiments, the corticosteroid is budesonide, e.g., at a dose ⁇ 9 mg/day, or an equivalent steroid.
  • the individual also is administered a therapeutic dose of an
  • the individual also is administered a therapeutic dose of a thiopurme. hi some embodiments, the individual also is administered a therapeutic dose of azathiopnne. In some embodiments, the individual also is administered a therapeutic dose of 6-mercaptopurine. In some embodiments, the individual also is administered a therapeutic dose of thioguanine (also referred to as tioguanine or 6-thioguanine). In some embodiments, the individual also is administered a therapeutic dose of a probiotic. In some embodiments, the individual also is administered a therapeutic dose of Culturelle. In some embodiments, the individual also is administered a therapeutic dose of Saccharomyces houlardii.
  • the individual also is administered a therapeutic dose of an antidiarrheal . In some embodiments, the individual also is administered a therapeutic dose of loperamide. In some embodiments, the individual also is administered a therapeutic dose of diphenoxylate with atropine.
  • Some embodiments of the present invention include a method of producing a pharmaceutical composition for“combination-therapy ” comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as described herein and a pharmaceutically acceptable carrier.
  • compositions comprising a standard dose of Compound 1, or, a phannaceutically acceptable salt, a hydrate or solvate thereof and, optionally, one or more pharmaceutically acceptable carriers.
  • pharmaceutical compositions comprising Compound 1, or, a pharmaceutically acceptable salt, a hydrate or solvate thereof, optionally, one or more pharmaceutically acceptable carriers.
  • the carrier(s) must he“acceptable” in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
  • Compound 1, or, a pharmaceutically acceptable salt, a hydrate or solvate thereof is administered as a raw or pure chemical, for example as a powder in capsule formulation.
  • Compound 1, or, a pharmaceutically acceptable salt, a hydrate or solvate thereof is formulated as a pharmaceutical composition further comprising one or more pharmaceutically acceptable carriers.
  • compositions may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, forming the resulting mixture into a desired shape.
  • the pharmaceutical composition may be in the form of, for example, a tablet or capsule.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
  • dosage units are capsules, tablets, powders, granules or suspensions, with conventional additives such as lactose, mannitol, com starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, com starch or gelatins; with disintegrators such as com starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or encapsulating materials.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desired shape and size.
  • the pow'ders and tablets may contain varying percentage amounts of the active compound.
  • a representative amount in a powder or tablet may be from 0.5 to about 90 percent of the active compound.
  • Suitable carriers for powders and tablets include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, a low' melting wax, cocoa butter, and the like.
  • the term "‘preparation” includes the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, pow'ders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets or capsules.
  • the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any of these in packaged form.
  • Formulations composed of immediate-release tablets containing an L-arginine salt of Compound 1 were prepared as shown in Table 2.
  • Compound 1 was evaluated for potential inhibition of the cytochrome P450 (CYP) enzymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5 (using two different marker substrates) and UDP -glucuronosyltransferase (UGT) enzymes UGT1A 1, UGT1 A3, UGT1A4, UGT1 A6, UGT1 A9, UGT2B7 and UGT2B17 in human liver microsomes, with the aim of ascertaining the potential of Compound 1 to inhibit the metabolism of concomitantly administered drugs.
  • CYP cytochrome P450
  • CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5 using two different marker substrates
  • UDP -glucuronosyltransferase (UGT) enzymes UGT1A 1, U
  • Compound 1 as a direct and metabolism-dependent inhibitor of CYP activity and as a direct inhibitor of UGT activity, human liver microsomes from a pool of 200 individuals were incubated with marker substrates in the presence or absence of Compound 1 at concentrations of 0, 1 or 10 mM.
  • Compound 1 was preincubated with human liver microsomes for 30 minutes with an NADPH-regenerating system, prior to the incubation with the marker substrates.
  • Known metabolism-dependent and/or direct inhibitors of CYP and UGT enzymes were included as positive controls, as applicable.
  • Direct inhibition of CYP2C8 activity was 22% at 1 mM and -100% at 10 mM in the presence of Compound 1. Little or no direct inhibition of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5 activities was observed in the presence of Compound 1 concentrations up to 10 mM. In addition, little or no evidence of metabolism-dependent inhibition of CYPs was seen.
  • Treatment of cultured human hepatocytes with Compound 1 was found to have no induction potential on CYP1A2 mRNA. Additionally, no induction potential for CYP2B6 and CYP3A4 was seen, based on induction criteria being a > 2-fold increase in mRNA and > 20% of the mRNA increase seen with positive control.
  • CYP2C8 and CYP2C9 were established to play major roles in conversion of Compound 1 to oxidative metabolites, and CYP2C8 also plays a major role in formation of a ketone metabolite.
  • the overall conversion of Compound 1 to metabolites was negligible in HLMs and there eas little difference in the loss of Compound 1 seen in the presence and absence of direct-acting and metabolism -dependent selective CYP inhibitors.
  • Direct inhibition of CYP2C8 activity was 22% at 1 mM and -100% at 10 mM in the presence of Compound 1. However, there was little or no direct inhibition observed for any other CYPs with Compound 1.
  • Compound 1 was evaluated as a potential substrate and/or inhibitor of human ABC transporters P- gp, BCRP and BSEP or human SLC transporters OATP1B1, OATP1B3, GATE OAT3, OCTl, OCT2, MATE1 and MATE2-K.
  • P-gp and BCRP are expressed on the apical membrane of a number of tissues.
  • P- gp and BCRP are expressed in the luminal membrane of enterocytes, endothelial cells in the brain, the brush border membrane of renal proximal tubules and the canalicular membrane of hepatocytes where they limit the intestinal absorption, blood-brain barrier penetration and facilitate excretion into the bile and urine BSEP is mainly expressed in the canalicular membrane of hepatocytes where it facilitates excretion into the bile.
  • OATP1 B1, OATP1B3 and OCTl are expressed on the sinusoidal membrane of hepatocytes and facilitate the accumulation of endogenous and xenobiotic compounds into hepatocytes for further metabolism or excretion into the bile.
  • OAT1, QAT3 and GCT2 are expressed on the basolateral membrane of renal proximal tubules and facilitate the accumulation of compounds into the proximal tubule for further excretion in the urine.
  • MATEl and MATE2-K are primarily expressed on the luminal (apical) membrane of the proximal tubular cells and thought to play a role in the excretion of cations and zwitterions into urine.
  • MATE1 is also expressed in the liver on the canalicular membrane of hepatocytes and mediates the biliary excretion of cationic drugs MATE!
  • MATE2-K may function in cooperation wi th OCT transporters expressed on the canalicular membranes of hepatocytes and the basolateral membranes of proximal tubules to mediate excretion.
  • Compounds that are substrates or inhibitors of the transporters may be victims or perpetrators in drag-drug interactions.
  • Madin-Darby canine kidney cells (MDCKII), over-expressing human permeability-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), were used to evaluate Compound 1 as a substrate of P- gp and BCRP. and as an inhibitor of BCRP.
  • a polarized cell line derived from a human colon carcinoma (Caeo 2) cells, was used to evaluate Compound 1 as an inhibitor of P-gp.
  • Membrane vesicles expressing bile salt export pump (BSEP) were used in a vesicular transport assay to evaluate Compound 1 as an inhibitor of BSEP.
  • Human embryonic kidney cells (HEK293) transfected with vectors containing human transporter cDNA for organic anion-transporting polypeptide 1B1 (OATP1B 1), organic anion-transporting polypeptide 1B3 (OATP1B3), organic anion transporter 1 (OATl), organic anion transporter 3 (OAT3), organic cation transporter 1 (OCTl), organic cation transporter 2 (OCT2) and control cells (HEK293 cells transfected with only vector) were used in experiments to evaluate Compound 1 as a substrate and an inhibitor of QATP1B1, OATP1B3, OATl, OAT3, OCTl and OCT2.
  • HEK293 ceils transfected with vectors containing renal multidrug and toxin extrusion transporters 1 and 2-K were used for evaluating Compound 1 as an inhibitor of MATE ! and MATE2-K.
  • Known substrates and inhibitors of ABC and SLC transporters were included as positive controls in all experiments.
  • the efflux ratio of Compound 1 (1 mM) across MDCKII-P-gp cells was 1.12 and increased to 3.08 m the presence of the P-gp inhibitor valspodar (10 mM).
  • the efflux ratio of Compound 1 (10 mM) across MDCKII-P-gp cells was 3.17 and did not reduce in the presence of valspodar.
  • the efflux ratio of Compound 1 across MDCKII-BCRP cells was less than two at I mM, and more than two at 10 mM in the absence and presence of the BCRP inhibitor Kol43 (1 mM). Although the efflux ratio of Compound 1 at 10 mM was 7.36 and was reduced to 3.17 in the presence of KoI43 ( 1 mM), the efflux ratio data of Compound 1 at 1 mM indicate Compound 1 is not a substrate of BCRP. For consideration as a substrate of the BCRP transporter, the efflux ratio of Compound 1 would be appreciably higher at lower concentration (1 mM) than at higher concentration (10 mM), and the consequent inhibition effect would likely be higher at a lower concentration (1 mM). It should be noted that Compound 1 recovery was low ranging from 27 to 48% and is likely due to non-specific binding to the plate.
  • Compound 1 was not a substrate of P-gp, BCRP, OATP1B1, OATP1B3, QAT1, OAT3, OCT1 and OCT2 transporters under the conditions evaluated.
  • Compound 1 inhibited P-gp, BCRP and OATP!B! with ICso values of -100, 35.7, and -10 mM, respectively.
  • Compound 1 (up to 10 mM) caused less than 50% inhibition of all the other transporters examined (BSEP, OATP1B3, OATl, OAT3, OCT1, OCT2, MATE1 and MATE2-K).
  • Compound 1 inhibited P-gp, BCRP and OATP1B1 with an IC50 values of -100, 35.7 and -10 mM, respectively.
  • Compound 1 (up to 10 mM) caused less than 50% inhibition of the other transporters examined (BSEP, OATP1B3, OATl, QAT3, OCT1, OCT2, MATE1 and MATE2-K). Compound 1 was found to have no inhibition potential with an ICSO > 10 mM on BSEP, OATP1B3, OATl, OATS, OCT1, GCT2, MATEI and MATE2-K transporters.
  • Compound 1 was evaluated to assess the single dose relative oral bioavailability of 2 mg tablet and capsule formulations in the fasted state, determine the effect of food on the pharmacokinetics of the 2 mg tablet, assess potential gender differences in Compound 1 pharmacokinetics, and evaluate safety and tolerability in healthy adult subjects.
  • a randomized, single-dose, open-label, three-period, cross-over, phase 1 study was conducted in healthy adult subjects.
  • a total of 14 subjects (7 males; 7 females) were randomized 1: 1 into two groups, Sequence 1 and Sequence 2.
  • the Sequence 1 group received a stngie 2 mg dose of the hard gelatin capsule formulation of Compound 1 (Treatment A)
  • the Sequence 2 group received a single 2 mg dose of the tablet formulation of Compound 1 (Treatment B).
  • the two groups crossed over in the second treatment period to receive the alternate treatment under fasted conditions.
  • Treatment C a single 2 mg dose of the tablet formulation of Compound 1 under fed conditions; i.e., FDA-standard lugh-fat high-calorie meal
  • Blood samples for determination of plasma concentrations of Compound 1 were collected at prespecified time points up to 120 hours post dose. Plasma samples were analyzed for Compound 1 using a validated LC/MS/MS assay.
  • the Compound 1 plasma concentration time data were analyzed by noncompartmental methods in PhoenixTM WinNonlin® (Version 6.3, Pharsight Corporation) to determine plasma pharmacokinetic parameters including peak concentration time to peak concentration (T, , ⁇ attire « ), and area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUCo- t ) or to infinity (AUC M ).
  • Safety and tolerability were evaluated using physical examination, ophthalmological examination, neurological and progressive multifocal leukoencephalopathy (PML) examination, vital sign measurements (supine blood pressure, heart rate, temperature, and respiratory' rate), clinical laboratory evaluations, electrocardiograms (ECGs), telemetry monitoring, tuberculosis (TB) screening, pulmonary function testing (PFT, using spirometry), and reported or observed adverse events (AEs).
  • PML progressive multifocal leukoencephalopathy
  • Compound 1 mean plasma concentrations and exposure parameters w3 ⁇ 4re only moderately higher in females compared to males across treatments. A total of eight AEs was reported by three subjects over the course of the study and consistent with what was seen previously in healthy volunteer studies. All AEs were considered treatment emergent, with only three AEs considered related to the administration of study medication. There were no serious AEs (SAEs) or AEs that led to sub j ect discontinuation. No clinically significant abnormalities in ECGs or physical exams were observed. There were no AEs related to clinically significant out-of-range vital signs.
  • SAEs serious AEs
  • EXAMPLE 6 Compound 1 (1 mg , 2 mg) is evaluated in an open-label, three-treatment, randomized, fixed sequence study to assess plasma pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in the presence and absence of dosing of fluconazole (a moderate inhibitor of CYP2C9), gemfibrozil (a strong inhibitor of CYP2C8), or rifampin (a moderate inducer of both CYP2C8 and CYP2C9) in healthy adult subjects.
  • PK plasma pharmacokinetics
  • PD pharmacodynamics
  • rifampin a moderate inducer of both CYP2C8 and CYP2C9 in healthy adult subjects.
  • Compound 1 Based on results from completed in vitro metabolism studies and a human mass balance clinical study, Compound 1 appears to be extensively metabolized (>25% overall) by oxidative (CYP2C8 and CYP2C9) and conjugation (UGT1 A7, minor extent UGT1 Al and UGT1 A4) pathways. Compound 1 is eliminated from the systemic circulation mainly due to metabolism and biliary/fecal excretion. Potential changes in Compound 1 pharmacokinetics are evaluated in the presence and absence of co-administered drugs that can impact one or more of these metabolism/elimination pathways— fluconazole or gemfi brozil due to the significant CYP inhibition effects, and rifampin due to the Significant CYP induction effects.
  • the study entails one of three treatments: 1) Compound 1 (1 mg) alone and in the presence of steady state fluconazole (400 mg loading dose followed by daily oral dose 200 mg); 2) Compound 1 (1 mg) alone and in the presence of steady state gemfibrozil (600 mg BID oral dose); and 3) Compound 1 (2 mg) alone and in the presence of steady state rifampin (600 mg daily oral dose).
  • Each treatment consists of two periods: period 1 (administration of a single oral dose of Compound 1 alone) and period 2 (administration of Compound 1 in the presence of an inhibitor or inducer drug). Each period will be separated by 7-day washout period.
  • Treatment A On day 8, subjects will be administered a single dose of fluconazole (400 mg) followed by once daily dosing of fluconazole (200 mg) up to day 23 On day 12, following an overnight fast of at least 8 hours, a single dose of Compound 1 (1 rng) will be administered 30 min following daily- dose of fluconazole.
  • Treatment B On day 8, subjects will be administered twice daily gemfibrozil (600 mg) up to day 23. On day 12, following an overnight fast of at least 8 hours, a single dose of Compound 1 ( 1 mg) will be administered 30 minutes following daily dose of gemfibrozil.
  • Treatment C On day 8, subjects will be administered once daily rifampin (600 mg) up to day 23. On day 15, following an overnight fast of at least 8 hours, a single dose of Compound 1 (2 mg) will be administered 30 min following daily dose of rifampin.
  • PK and PD profiles of Compound 1 are assessed after dose administration on day 1 (Compound 1 alone) and day 12/15 (in the presence of steady-state CYP2C8/CYP2C9 inhibitor or inducer). Measured PK parameters will include the following assessed using an analysis of covariance model for each comparison (i.e., Compound 1 alone versus the CYP2C8/CYP2C9 inhibitor or inducer):
  • AUC0-168 area under the concentration -time curve (AUC) zero to 168 hour calculated using the linear-log trapezoidal rule
  • AUClast AUC from time zero to the time of the last quantifiable concentration (tlast) calculated using the linear-log trapezoidal rule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PCT/US2019/035662 2018-06-06 2019-06-05 Methods of treating conditions related to the s1p1 receptor Ceased WO2019236757A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2020013157A MX2020013157A (es) 2018-06-06 2019-06-05 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
JP2020567825A JP7397011B2 (ja) 2018-06-06 2019-06-05 Ｓ１ｐ１受容体に関連する状態を治療する方法
ES19739424T ES2987794T3 (es) 2018-06-06 2019-06-05 Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CA3102136A CA3102136A1 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the s1p1 receptor
KR1020217000401A KR102859841B1 (ko) 2018-06-06 2019-06-05 S1p1 수용체와 관련된 병태의 치료 방법
US15/734,920 US12156866B2 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the S1P1 receptor
EP19739424.0A EP3801459B1 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the s1p1 receptor
AU2019280822A AU2019280822A1 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the S1P1 receptor
CN201980051786.0A CN112601516A (zh) 2018-06-06 2019-06-05 治疗与s1p1受体相关的病况的方法
BR112020024762-6A BR112020024762A2 (pt) 2018-06-06 2019-06-05 métodos de tratamento de condições relacionadas ao receptor s1p1
IL279180A IL279180A (en) 2018-06-06 2020-12-03 Methods of treating conditions related to the S1P1 receptor
US18/964,847 US20250090497A1 (en) 2018-06-06 2024-12-02 Methods of treating conditions related to the s1p1 receptor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862681426P 2018-06-06 2018-06-06
US62/681,426 2018-06-06
US201862746946P 2018-10-17 2018-10-17
US62/746,946 2018-10-17
US201962850470P 2019-05-20 2019-05-20
US62/850,470 2019-05-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/734,920 A-371-Of-International US12156866B2 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the S1P1 receptor
US18/964,847 Continuation US20250090497A1 (en) 2018-06-06 2024-12-02 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
WO2019236757A1 true WO2019236757A1 (en) 2019-12-12

Family

ID=67253955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/035662 Ceased WO2019236757A1 (en) 2018-06-06 2019-06-05 Methods of treating conditions related to the s1p1 receptor

Country Status (13)

Country Link
US (2) US12156866B2 (enExample)
EP (1) EP3801459B1 (enExample)
JP (1) JP7397011B2 (enExample)
KR (1) KR102859841B1 (enExample)
CN (1) CN112601516A (enExample)
AU (1) AU2019280822A1 (enExample)
BR (1) BR112020024762A2 (enExample)
CA (1) CA3102136A1 (enExample)
ES (1) ES2987794T3 (enExample)
IL (1) IL279180A (enExample)
MA (1) MA52778A (enExample)
MX (1) MX2020013157A (enExample)
WO (1) WO2019236757A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163355A1 (en) * 2020-02-11 2021-08-19 Arena Pharmaceuticals, Inc. Formulations and methods of treating conditions related to the s1p1 receptor
US11674163B2 (en) 2010-01-27 2023-06-13 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
US11896578B2 (en) 2015-01-06 2024-02-13 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US20210386706A1 (en) * 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2016112075A1 (en) * 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2018151873A1 (en) * 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018151834A1 (en) * 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations

Family Cites Families (515)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389134A (de) 1960-03-15 1965-03-15 Ciba Geigy Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
NL293572A (enExample) 1962-06-07
CH478819A (de) 1965-10-22 1969-09-30 Ciba Geigy Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (enExample) 1967-10-17 1970-06-01
US3608087A (en) 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (fr) 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de) 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en) 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US3966764A (en) 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (enExample) 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4101541A (en) 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (enExample) 1973-12-21 1977-02-15 Ciba Geigy Ag
FR2258841B1 (enExample) 1974-01-29 1977-11-04 Ugine Kuhlmann
AT327605B (de) 1974-05-06 1976-02-10 Ciba Geigy Ag Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en) 1974-05-14 1975-11-20 Ciba-Geigy Ag Nitropyrimidine derivatives
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
US4139705A (en) 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de) 1978-07-20 1980-02-07 Basf Ag N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de) 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
DE3070304D1 (en) 1980-04-28 1985-04-25 Teijin Ltd Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
RU938559C (ru) 1980-12-12 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе S-Производные 5-амино-6-меркаптопиримидина, обладающие противоопухолевым и цитостатическим действием
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3334455A1 (de) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS6157587A (ja) 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
AU601145B2 (en) 1985-03-01 1990-09-06 Duphar International Research B.V. Benzoyl urea derivatives having anti-tumor activity
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
CA1340284C (en) 1987-03-19 1998-12-22 Zeneca Inc. Herbicidal substituted cyclic diones
DE68926687T2 (de) 1988-01-11 1997-03-06 Fuji Photo Film Co Ltd Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern
US4782076A (en) 1988-03-01 1988-11-01 American Home Products Corporation Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
NZ238863A (en) 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
EP0567643A4 (en) 1991-01-16 1995-07-19 Yoshitomi Pharmaceutical PYRIDINE COMPOUND USED AS A SELECTIVE DRUG AND NEW PYRIDINE COMPOUND.
CA2070978A1 (en) 1991-06-11 1992-12-12 William J. Greenlee Cyclic renin inhibitors
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JPH0533359A (ja) 1991-08-02 1993-02-09 Kubota Corp 全旋回型の小型バツクホウ
EP0556889A1 (en) 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
TW237456B (enExample) 1992-04-09 1995-01-01 Ciba Geigy
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
NZ274978A (en) 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
GB9400889D0 (en) 1994-01-18 1994-03-16 Sandoz Ltd Novel compounds
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
CN1118454C (zh) 1994-09-09 2003-08-20 日本新药株式会社 杂环衍生物和医药
SK281865B6 (sk) 1994-11-29 2001-08-06 Dainippon Pharmaceutical Co., Ltd. Indolový derivát a jeho optický izomér, spôsob jeho prípravy a farmaceutický prostriedok
CA2214685C (en) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033994A1 (en) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
US6020492A (en) 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
WO1996036613A1 (en) 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Substituted benzoic acid derivatives, process for the production thereof, and herbicides
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0169813B1 (ko) 1995-07-12 1999-01-15 김종인 4-아미노-3-아실나프티리딘 유도체
ATE197150T1 (de) 1995-08-31 2000-11-15 Lonza Ag Verfahren zur herstellung von dihydroxypyrimidin- derivaten
DE69628051T2 (de) 1995-10-26 2004-02-26 Mitsubishi Pharma Corp. Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
DE19602095A1 (de) 1996-01-22 1997-07-24 Bayer Ag Halogenpyrimidine
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
CZ244598A3 (cs) 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
DK0929547T3 (da) 1996-09-12 2003-03-10 Schering Ag Benzamidinderivater substitueret af cykliske aminosyrederivater eller cykliske hydroxysyrederivater og deres anvendelse som antikoagulantia
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL123232A0 (en) 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
PT977737E (pt) 1997-04-22 2004-02-27 Janssen Pharmaceutica Nv Quino- e quinazolinas antagonistas de crf
US6211195B1 (en) 1997-04-22 2001-04-03 Neurocrine Biosciences, Inc. CRF antagonistic thiophenopyridines
JPH11193277A (ja) 1997-05-14 1999-07-21 Nippon Soda Co Ltd ピリミジン誘導体、その製法および有害生物防除剤
DE19737723A1 (de) 1997-08-14 1999-02-18 Bayer Ag Methoximinomethyloxadiazine
JP2001515076A (ja) 1997-08-14 2001-09-18 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤として使用されるメトキシイミノメチルオキサジアジン
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
EP1105394A1 (en) 1998-08-21 2001-06-13 Du Pont Pharmaceuticals Company ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
ES2308759T3 (es) 1998-11-20 2008-12-01 Arena Pharmaceuticals, Inc. Receptores acoplados a proteina g humanos huerfanos.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP2002532472A (ja) 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ１ａ受容体活性を有するアリールピペリジンおよびアリール−１，２，５，６−テトラヒドロピリジン尿素誘導体
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
JP2002532479A (ja) 1998-12-18 2002-10-02 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼインヒビター
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
HUP0105114A3 (en) 1999-03-17 2002-09-30 Astrazeneca Ab Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
KR20020027463A (ko) 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
DE60004685T2 (de) 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
PL354982A1 (en) 1999-09-30 2004-03-22 Neurogen Corporation Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
GR990100388A (el) 1999-11-09 2001-07-31 Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
WO2001046204A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
TR200201684T2 (tr) 1999-12-30 2002-10-21 H. Lundbeck A/S Fenilpiperazinil türevleri
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
SK11202002A3 (sk) 2000-02-09 2003-03-04 Hokuriku Seiyaku Co., Ltd. Deriváty 1H-imidazopyridínu
JP2003523418A (ja) 2000-02-15 2003-08-05 フオスター・ミラー・インコーポレイテツド 揮発性有機成分を含まない放射硬化性樹脂組成物
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
CA2398274C (en) 2000-02-25 2009-09-22 F. Hoffmann-La Roche Ag Adenosine receptor modulators
PE20020229A1 (es) 2000-04-12 2002-04-11 Novartis Ag COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
DE10024319A1 (de) 2000-05-17 2001-11-22 Merck Patent Gmbh Bisacylguanidine
AU2001263288A1 (en) 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists
EP1287133B1 (en) 2000-05-18 2006-12-13 Bayer HealthCare AG Regulation of human dopamine-like g protein-coupled receptor
CN1187342C (zh) 2000-05-25 2005-02-02 弗·哈夫曼-拉罗切有限公司 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
HRP20030027A2 (en) 2000-06-28 2004-02-29 Teva Pharma Carvedilol
AU2001268718B2 (en) 2000-06-29 2006-01-05 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
PL359416A1 (en) 2000-07-18 2004-08-23 Yamanouchi Pharmaceutical Co, Ltd. Medicine comprising dicyanopyridine derivative
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2002019975A1 (fr) 2000-09-05 2002-03-14 Taisho Pharmaceutical Co., Ltd. Stimulants de la croissance des cheveux
EP1322289B1 (en) 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
EP1347755A2 (en) 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
ES2279835T3 (es) 2000-11-03 2007-09-01 Neurocrine Biosciences, Inc. Antagonistas del receptor de crf y metodos relacionados.
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
AU2002223492A1 (en) 2000-11-14 2002-05-27 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
CA2429426A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
KR100846339B1 (ko) 2000-11-20 2008-07-15 바이오비트럼 에이비(피유비엘) 세로토닌 5ｈｔ-2 수용체의 아고니스트 또는안타고니스트로서의 피페라지닐피라진 화합물
AU2002218509A1 (en) 2000-12-01 2002-06-11 Yamanouchi Pharmaceutical Co..Ltd. Method of screening remedy for diabetes
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2002237988B2 (en) 2001-01-30 2008-01-03 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
US7342021B2 (en) 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
WO2002079131A1 (en) 2001-03-29 2002-10-10 Kansai Research Institute, Inc. Optically active compound and photosensitive resin composition
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6815456B2 (en) 2001-04-20 2004-11-09 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1391199B1 (en) 2001-05-10 2008-12-10 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
ATE448210T1 (de) 2001-06-01 2009-11-15 Hoffmann La Roche Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1406875B1 (en) 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
EP1467729A1 (en) 2002-01-18 2004-10-20 The Genetics Company Inc. Beta-secretase inhibitors
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
AU2003218056A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1482895A4 (en) 2002-03-01 2005-04-27 Merck & Co Inc AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
AU2003228283A1 (en) 2002-03-07 2003-09-22 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
US7731985B2 (en) 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
TW200810743A (en) 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
AU2003225027A1 (en) 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
EP1499598A1 (en) 2002-04-18 2005-01-26 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2005531606A (ja) 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
CA2488499C (en) 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
EP1511467A1 (en) 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP1549336B1 (en) 2002-06-14 2011-01-05 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of ulcerative colitis using pyy or pyy[3-36]
AU2003276043A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10226943A1 (de) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
EP1531832B1 (en) 2002-06-28 2009-04-15 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
EP1534389A2 (en) 2002-07-23 2005-06-01 SmithKline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004009602A1 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
EP1523314A2 (en) 2002-07-23 2005-04-20 SmithKline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003258542A1 (en) 2002-07-29 2004-02-23 Axxima Pharmaceuticals Ag Method for isolating atp binding proteins by means of immobolized protein inhibitors
CA2491733A1 (en) 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
US7297715B2 (en) 2002-07-30 2007-11-20 Merck & Co., Inc. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
AU2003259296A1 (en) 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
JP2004067575A (ja) 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
AR041191A1 (es) 2002-08-08 2005-05-04 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US20060167045A1 (en) 2002-08-21 2006-07-27 Joanne Waldstreicher Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist
HRP20050181A2 (en) 2002-08-29 2006-03-31 Merck & Co. Inc. Indoles having anti-diabetic activity
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004024943A1 (ja) 2002-09-11 2004-03-25 Yamanouchi Pharmaceutical Co., Ltd. インスリン含量増加剤スクリーニング方法
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003284111A1 (en) 2002-10-09 2004-05-04 Genaissance Pharmaceuticals, Inc. Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CA2510793A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1581509B1 (en) 2002-12-20 2011-01-19 Merck Sharp & Dohme Corp. 1-(amino)indanes as edg receptor agonists
GB0230020D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
GB0230021D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE359782T1 (de) 2003-01-16 2007-05-15 Sb Pharmco Inc Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
CA2512879A1 (en) 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
US7256206B2 (en) 2003-02-11 2007-08-14 Irm Llc Bicyclic compounds and compositions
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
CN100344638C (zh) 2003-02-18 2007-10-24 杏林制药株式会社 氨基膦酸衍生物、其加成盐以及s1p受体调节剂
JP2006518763A (ja) 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ， インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
JP2004269468A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
OA13153A (en) 2003-03-28 2006-12-13 Pfizer Prod Inc 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydroquinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity.
CA2523677A1 (en) 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
CA2523743A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
ATE547395T1 (de) 2003-04-30 2012-03-15 Novartis Pharma Gmbh Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
DE60333546D1 (de) 2003-05-06 2010-09-09 Univ Palackeho PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004104205A2 (en) 2003-05-16 2004-12-02 Merck & Co., Inc. Enzymatic preparation of chiral indole esters
BRPI0410454A (pt) 2003-05-19 2006-06-13 Irm Llc composições e compostos imunossupressores
JP4728962B2 (ja) 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US20060160834A1 (en) 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
AU2003902882A0 (en) 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2292620A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
DK2287156T3 (da) 2003-08-15 2013-08-26 Novartis Ag 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
CN101407471A (zh) 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
JP2007504230A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc NEW CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR
US7692017B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US20060089335A1 (en) 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005046603A2 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
AR046778A1 (es) 2003-11-12 2005-12-21 Phenomix Corp Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
ATE528276T1 (de) 2003-12-19 2011-10-15 Ono Pharmaceutical Co Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CN1898235A (zh) 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
EP1718604A4 (en) 2004-02-24 2008-02-13 Irm Llc COMPOUNDS AND COMPOSITIONS OF IMMUNOSUPPRESSANTS
CN1934094A (zh) 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
AU2005230897B2 (en) 2004-04-02 2011-03-03 Merck Sharp & Dohme Corp. Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives
CN1968954A (zh) 2004-04-12 2007-05-23 三共株式会社 噻吩并吡啶衍生物
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
EP1772145B1 (en) 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
EP1798226A4 (en) 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd TRAIZOL DERIVATIVE
JP2008509931A (ja) 2004-08-13 2008-04-03 プレーシス ファーマスーティカルズ インコーポレイテッド スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物
US20060223866A1 (en) 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
CN101090724A (zh) 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
US7250441B2 (en) 2004-09-23 2007-07-31 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
BRPI0515992A (pt) 2004-10-12 2008-08-19 Forbes Medi Tech Res Inc compostos e métodos para o tratamento de resistência à insulina e cardiomiopatia
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
DE602004014277D1 (de) 2004-10-22 2008-07-17 Bioprojet Soc Civ Neue Dicarbonsäurederivate
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP5785354B2 (ja) 2004-11-03 2015-09-30 アリーナ ファーマシューティカルズ， インコーポレイテッド インスリン関連障害の処置のためのｇｐｒ４１およびその調節因子
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
AU2005307718A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
WO2006057448A1 (ja) 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
TW200633720A (en) 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
BRPI0516407A (pt) 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
CA2595205A1 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
JP5798282B2 (ja) 2005-01-25 2015-10-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ メソゲン性化合物、液晶媒体および液晶ディスプレイ
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
US7846964B2 (en) 2005-03-23 2010-12-07 Actelion Pharmaceuticals Ltd. Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists
EP1863787B1 (en) 2005-03-23 2011-05-25 Actelion Pharmaceuticals Ltd. Hydogrenated benzo[c]thiophene derivatives as immunomodulators
CN101146529B (zh) 2005-03-23 2012-08-29 埃科特莱茵药品有限公司 新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
CA2611446A1 (en) 2005-06-09 2006-12-14 Banyu Pharmaceutical Co., Ltd. Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
CA2612661A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
MX2007016066A (es) 2005-07-01 2008-03-10 Irm Llc Derivados de bencimidazol sustituidos por pirimidina como inhibidores de cinasa de proteina.
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
DE602006006461D1 (de) 2005-09-16 2009-06-04 Arena Pharm Inc Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
WO2007037196A1 (ja) 2005-09-29 2007-04-05 Yamamoto Chemicals, Inc. インドリン系化合物及びその製造方法
KR101297302B1 (ko) 2005-10-07 2013-08-19 교린 세이야꾸 가부시키 가이샤 2-아미노-1,3-프로판디올 유도체를 유효성분으로 하는간장질환 치료제 및 간장질환 치료방법
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
WO2007089335A2 (en) 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
AU2006335967B2 (en) 2006-01-19 2012-01-19 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
JP5063615B2 (ja) 2006-01-24 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド 新規ピリジン誘導体
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
AU2007214434B2 (en) 2006-02-15 2012-06-14 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101384566A (zh) 2006-02-21 2009-03-11 弗吉尼亚大学专利基金会 作为s1p受体激动剂的苯基-环烷基和苯基-杂环衍生物
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2009530281A (ja) 2006-03-14 2009-08-27 アムジエン・インコーポレーテツド 代謝障害の治療に有用である二環式カルボン酸誘導体
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
AU2007238805B2 (en) 2006-04-11 2012-04-05 Arena Pharmaceuticals, Inc. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
BRPI0711358A2 (pt) 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
US20090324581A1 (en) 2006-05-09 2009-12-31 Daiichi Sankyo Company Limited Heteroarylamide lower carboxylic acid derivative
WO2007129473A1 (ja) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited 二環性アリール誘導体
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008008887A2 (en) 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
AR062156A1 (es) 2006-08-01 2008-10-22 Praecis Pharm Inc Compuestos agonistas y selectivos del receptor s1p-1
US20080070866A1 (en) 2006-08-01 2008-03-20 Praecis Pharmaceuticals Incorporated Chemical compounds
US20090318389A1 (en) 2006-08-04 2009-12-24 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1 phosphate receptor
PL2058317T3 (pl) 2006-08-08 2014-03-31 Kyorin Seiyaku Kk Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny
WO2008024196A1 (en) 2006-08-24 2008-02-28 Praecis Pharmaceuticals Incorporated Chemical compounds
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
EP2059516A1 (en) 2006-08-30 2009-05-20 BIOVITRUM AB (publ) Pyridine compounds for treating gpr119 related disorders
MY149853A (en) 2006-09-07 2013-10-31 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
CA2662852A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
CA2662091A1 (en) 2006-09-08 2008-03-13 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
KR20090051774A (ko) 2006-09-21 2009-05-22 액테리온 파마슈티칼 리미티드 페닐 유도체 및 면역조절제로서 이들의 용도
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
CA2672059A1 (en) 2006-12-14 2008-06-26 Merck & Co., Inc. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
UY30829A1 (es) 2006-12-21 2008-07-31 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
CA2674946A1 (en) 2007-01-11 2008-07-24 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
MX2009010060A (es) 2007-03-21 2010-01-20 Epix Pharm Inc Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
WO2008128832A1 (en) 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
CA2684385A1 (en) 2007-04-19 2008-10-30 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
WO2009019167A1 (en) 2007-08-08 2009-02-12 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
TW200930368A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
EP2225201A2 (en) 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
ATE531711T1 (de) 2007-12-18 2011-11-15 Arena Pharm Inc Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
WO2009108924A2 (en) 2008-02-28 2009-09-03 Solar Roofing Systems, Inc. Photovoltaic roofing tile with fire suppression
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2271619A1 (en) 2008-04-07 2011-01-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009125434A2 (en) 2008-04-07 2009-10-15 Cadila Healthcare Limited Oxime derivatives
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer
WO2009151621A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
HRP20151190T1 (hr) 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
US8410122B2 (en) 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
WO2010084944A1 (ja) 2009-01-22 2010-07-29 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
PE20120578A1 (es) 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
ES2759949T3 (es) 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MTP4285B (en) 2009-12-30 2011-07-04 Medichem Sa A 1-(1h-1,2,3-triazol-1-yl)butan-2-ol derivative for pharmaceutical use, and the use of a 1-(1h-1, 2, 4- triazol-1yl) butan-2-ol derivative with substially undefined crystal shap for preparing said 1-(1h-1, 2, 4-triazol-1-yl0 butan-2-ol derivative
EP2542554B1 (en) 2010-03-03 2015-11-04 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
PT2672823T (pt) 2011-02-07 2016-11-21 Biogen Ma Inc Agentes que modulam s1p
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US8962888B2 (en) 2012-12-03 2015-02-24 Physical Sciences, Inc. Forming spherical crystal habit
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
EP3199947A3 (en) 2013-04-04 2017-09-13 Novartis AG Identifying patient response to s1p receptor modulator administration
WO2014179738A1 (en) 2013-05-03 2014-11-06 Syndax Pharmaceuticals, Inc. Methods for the treatment of cancer
SG11201704827UA (en) * 2014-12-16 2017-07-28 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
US20180016244A1 (en) 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
US20210386706A1 (en) 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma
KR102824401B1 (ko) 2018-11-30 2025-06-25 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2020146529A1 (en) 2019-01-08 2020-07-16 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2016112075A1 (en) * 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2018151873A1 (en) * 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018151834A1 (en) * 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations

Non-Patent Citations (93)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis", ARENA PHARMACEUTICALS PRESS RELEASES, 19 March 2018 (2018-03-19), XP055617285, Retrieved from the Internet <URL:http://invest.arenapharm.com/node/18666/pdf> [retrieved on 20190902] *
BALATONI ET AL., BRAIN RESEARCH BULLETIN, vol. 74, 2007, pages 307 - 316
BAUMRUKER ET AL., EXPERT OPIN. INVESTIG. DRUGS, vol. 16, 2007, pages 505 - 518
BAUMRUKER, EXPERT. OPIN. INVESTIG. DRUGS, vol. 16, 2007, pages 283 - 289
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
BOLICK ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 25, 2005, pages 976 - 981
BRINKMANN ET AL., J. BIOI. CHEM., vol. 277, 2002, pages 21453 - 21457
BRINKMANN ET AL., PHARMACOLOGY & THERAPEUTICS, vol. 115, 2007, pages 84 - 105
BRINKMANN ET AL., TRANSPLANT PROC., vol. 33, 2001, pages 530 - 531
BRINKMANN ET AL., TRANSPLANT. PROC., vol. 33, 2001, pages 530 - 531
BRINKMANN ET AL., TRANSPLANTATION, vol. 72, 2001, pages 764 - 769
BROSSARD ET AL., BR J CLIN PHARMACOL, 18 April 2013 (2013-04-18)
BUDDE ET AL., J. AM. SOC. NEPHROL., vol. 13, 2002, pages 1073 - 1083
CHIBA ET AL., CELL MOL. BIOL., vol. 3, 2006, pages 11 - 19
CHIBA, PHARMACOLOGY & THERAPEUTICS, vol. 108, 2005, pages 308 - 319
CHUN ET AL., PHARMACOLOGICAL REVIEWS, vol. 54, 2002, pages 265 - 269
COELHO ET AL., J. PHARMACOL. EXP. THER., vol. 323, 2007, pages 626 - 635
D. NAKASHIMA ET AL., J. INVESTIGATIVE DERMATOLOGY, vol. 128, no. 12, 2008, pages 2833 - 2841
DANIEL ET AL., J. IMMUNOL., vol. 178, 2007, pages 2458 - 2468
DEGUCHI ET AL., ONCOLOGY REPORTS, vol. 16, 2006, pages 699 - 703
DEV ET AL., PHARMACOLOGY AND THERAPEUTICS, vol. 117, 2008, pages 77 - 93
E. BAR-HAIM ET AL., PLOS PATHOGENS, vol. 4, no. 11, 21 November 2008 (2008-11-21), pages e 1000211
FUJII ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 291, 2006, pages G267 - G274
FUJINO ET AL., J. PHARMACOL. EXP. THER., vol. 305, 2003, pages 70 - 77
FUJISHIRO ET AL., J. HEART LUNG TRANSPLANT, vol. 25, 2006, pages 825 - 833
GERGELY, BR J PHARMACOL, vol. 167, no. 5, 2012, pages 1035 - 1047
HALE ET AL., BIOORG. MED CHEM. LETT., vol. 14, 2004, pages 3351 - 3355
HALE ET AL., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 3351 - 3355
HERZINGER, AM. J. CLIN. DERMATOL., vol. 8, 2007, pages 329 - 336
HWANG ET AL., CIRCULATION, vol. 100, 1999, pages 1322 - 1329
IDZKO ET AL., J. CLIN. INVEST., vol. 116, 2006, pages 2935 - 2944
ISHII ET AL., NATURE, 8 February 2009 (2009-02-08)
JOHAN GROENEVELD, VASCUL. PHARMACOL., vol. 39, 2003, pages 247 - 256
JUNG ET AL., GLIA, vol. 55, 2007, pages 1656 - 1667
K,J. GUILLORY: "Polymorphism in Pharmaceutical Solids", vol. 95, 1999, MARCEL DEKKER. INC., article "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", pages: 202 - 209
KANEIDER ET AL., FASEB J., vol. 18, 2004, pages 309 - 311
KAPPOS ET AL., N. ENGL. J. MED., vol. 355, 2006, pages 1124 - 1140
KATAOKA ET AL., CELLULAR & MOLECULAR IMMUNOLOGY, vol. 2, 2005, pages 439 - 448
KAUDEL, TRANSPLANT. PROC., vol. 39, 2007, pages 499 - 502
KEUL, ARTERIOSCLER. THROMB. VASC. BIOL, vol. 27, 2007, pages 607 - 613
KIM, CELL SIGNAL, vol. 16, 2004, pages 89 - 95
KIMURA ET AL., STEM CELLS, vol. 25, 2007, pages 115 - 124
KIYABAYASHI ET AL., J. CARDIOVASC. PHARMACOL., vol. 35, 2000, pages 410 - 416
KOHNO ET AL., BIOL. PHARM. BULL., vol. 27, 2004, pages 1392 - 1396
KORECK ET AL., DERMATOLOGY, vol. 206, 2003, pages 96 - 105
KOVARIK ET AL., J CLIN PHARMACOL, vol. 44, no. 5, 2004, pages 532 - 537
KUROSE ET AL., EXP. EYE RES., vol. 70, 2000, pages 7 - 15
LAMONTAGNE ET AL., CANCER RES., vol. 66, 2006, pages 221 - 231
LEE ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 84588466
LIMA ET AL., TRANSPLANT PROC., vol. 36, 2004, pages 1015 - 1017
LIU ET AL., MICROSURGERY, vol. 27, 2007, pages 300 - 304
MAKI ET AL., TRANSPLANTATION, vol. 105, 2005, pages 1 - 1055
MAKI ET AL., TRANSPLANTATION, vol. 74, 2002, pages 1684 - 1686
MARTINI ET AL., AM..J. PHYSIOL. RENAL PHYSIOL., vol. 292, 2007, pages F1761 - F1770
MATLOUBIAN ET AL., NATURE, vol. 427, 2004, pages 355 - 360
MATSUURA ET AL., INFLAMM. RES., vol. 49, 2000, pages 404 - 410
MATSUURA ET AL., INT. J. IMMUNOPHARMACOL., vol. 22, 2000, pages 323 - 331
MIRON ET AL., ANN. NEUROL., vol. 63, 2008, pages 61 - 71
MIYAMOTO ET AL., J. AM. COLL. CARDIOL., vol. 37, 2001, pages 1713 - 1718
MIZUSHIMA ET AL., INFLAMM. BOWEL DIS., vol. 10, 2004, pages 182 - 192
NOFER ET AL., CIRCULATION, vol. 115, 2007, pages 501 - 508
O. COSTU ET AL., JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 12, no. 3, 2008, pages 995 - 1004
OGAWA ET AL., BBRC, vol. 361, 2007, pages 621 - 628
OKAZAKI ET AL., J. RHEUMATOL., vol. 29, pages 707 - 716
OO ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 9082 - 9089
PAN ET AL., CHEMISTRY & BIOLOGY, vol. 13, 2006, pages 1227 - 1234
PREMENKO-LANIER ET AL., NATURE, vol. 454, 2008, pages 894
RAUSCH, J. MAGN. RESON. IMAGING, vol. 20, 2004, pages 16 - 24
RAVENEY ET AL., ARCH. OPHTHALMOL., vol. 126, no. 10, 2008, pages 1390
REMINGTON: "The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
ROSEN ET AL., IMMUNOL. REV., vol. 195, 2003, pages 160 - 177
SAKAGAWA ET AL., TRANSPL. IMMUNOL., vol. 13, 2004, pages 161 - 168
SANNA ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 13839 - 13848
SANNA ET AL., NAT. CHEM. BIOL., vol. 2, 2006, pages 434 - 441
SAUER ET AL., J. BIOI. CHEM., vol. 279, 2004, pages 38471 - 38479
SAWICKA ET AL., J. IMMUNOL., vol. 171, 2003, pages 6206 - 6214
SCHMID, J. CELL BIOCHEM., vol. 101, 2007, pages 259 - 270
SCHWAB ET AL., NATURE IMMUNOL., vol. 8, 2007, pages 1295 - 1301
SHIMIZU ET AL., CIRCULATION, vol. 11, no. 1, 2005, pages 222 - 229
SUZUKI ET AL., TRANSPL. IMMUNOL., vol. 4, 1996, pages 252 - 255
T SANCHEZ ET AL., J. BIOI. CHEM., vol. 278, no. 47, 2003, pages 47281 - 47290
T. HIGUCHIV. STELLA: "Bioreversihle Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Prodrugs as Novel Delivery Systems"
T. KOHONO ET AL., BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 28, no. 4, 2005, pages 736 - 739
TAYLOR ET AL., BLOOD, vol. 110, 2007, pages 3480 - 3488
TNIONG ET AL., AMERICAN JOURNAL OF TRANSPLANTATION, vol. 7, 2007, pages 2031 - 2038
WEBB ET AL., J. NEUROIMMUNOL, vol. 153, 2004, pages 108 - 121
WEBSTER, CUTIS, vol. 76, no. 2, 2005, pages 4 - 7
WHETZEL ET AL., CIRC. RES., vol. 99, 2006, pages 731 - 739
YAN ET AL., BIOORG. & A-FED. CHEM. LEFT., vol. 16, 2006, pages 3679 - 3683
YANAGAWA ET AL., J. IMMUNOL., vol. 160, 1998, pages 5493 - 5499
YANG ET AL., CLINICAL IMMUNOLOGY, vol. 107, 2003, pages 30 - 35
ZHANG ET AL., J. CELL. MOL. MED., vol. 11, 2007, pages 307 - 314
ZHANG ET AL., MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 7, 2007, pages 845 - 850

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11674163B2 (en) 2010-01-27 2023-06-13 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
US11896578B2 (en) 2015-01-06 2024-02-13 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2021163355A1 (en) * 2020-02-11 2021-08-19 Arena Pharmaceuticals, Inc. Formulations and methods of treating conditions related to the s1p1 receptor
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
TWI855501B (zh) * 2022-01-13 2024-09-11 美商艾尼納製藥公司 治療方法

Also Published As

Publication number Publication date
KR20210029190A (ko) 2021-03-15
BR112020024762A2 (pt) 2021-03-23
AU2019280822A1 (en) 2021-01-07
EP3801459A1 (en) 2021-04-14
AU2019280822A8 (en) 2021-01-28
US20250090497A1 (en) 2025-03-20
CN112601516A (zh) 2021-04-02
MX2020013157A (es) 2021-04-29
KR102859841B1 (ko) 2025-09-12
US12156866B2 (en) 2024-12-03
CA3102136A1 (en) 2019-12-12
JP7397011B2 (ja) 2023-12-12
IL279180A (en) 2021-01-31
EP3801459B1 (en) 2024-08-07
JP2021527050A (ja) 2021-10-11
US20210228545A1 (en) 2021-07-29
MA52778A (fr) 2021-04-21
ES2987794T3 (es) 2024-11-18

Similar Documents

Publication Publication Date Title
US20250090497A1 (en) Methods of treating conditions related to the s1p1 receptor
US11896578B2 (en) Methods of treating conditions related to the S1P1 receptor
KR102824401B1 (ko) S1p1 수용체와 관련된 병태의 치료 방법
HK40050237A (en) Methods of treating conditions related to the s1p1 receptor
HK40050237B (en) Methods of treating conditions related to the s1p1 receptor
HK40111393A (en) Compound for use in treating conditions related to the s1p1 receptor
HK1240134B (en) Compound for use in treating conditions related to the s1p1 receptor
HK1240134A1 (en) Compound for use in treating conditions related to the s1p1 receptor
EA044252B1 (ru) Способы лечения состояний, связанных с рецептором s1p1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19739424

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3102136

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020567825

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020024762

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019280822

Country of ref document: AU

Date of ref document: 20190605

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019739424

Country of ref document: EP

Effective date: 20210111

ENP Entry into the national phase

Ref document number: 112020024762

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201203

WWW Wipo information: withdrawn in national office

Ref document number: 2019739424

Country of ref document: EP